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1 ABSTRACT 
Distinguishing patients with active tuberculosis (TB) from those with latent TB is an 
important clinical problem. The SELDI-TOF MS (Surface Enhanced Laser 
Desorption Ionisation – Time of Flight Mass Spectrometry) platform allows for high 
throughput detection of multiple proteins in biological fluids. Proteomic patterns 
reflecting host-pathogen interaction can be used as a tool to aid our understanding of 
the Natural History of Tuberculosis. 
Methods: Plasma samples were collected prospectively in a shanty town in Lima, 
Peru. Latent and active TB status was defined using the Tuberculin Skin Test (TST), 
Quantiferon (QFN) assay and TB culture. Crude plasma and fractionated plasma 
samples were analysed on weak cationic CM10 chip surfaces using a Biomek 3000 
Laboratory Automation Workstation. Spectra were generated using a ProteinChip 
System 4000 Mass spectrometer. Data was analysed using a Support Vector Machine. 
Results: 
Samples were collected from 154 patients with active TB, 112 patients with 
respiratory symptoms suggestive of TB and 151 healthy controls. Multiple peaks 
differed significantly between active TB patients and unhealthy controls. Trained 
optimal classifiers discriminate between:  
i) active TB and unhealthy controls with 84% accuracy (87% sensitivity, 79% 
specificity) in crude plasma and up to 89% accuracy (90% sensitivity, 88% 
specificity) in fractionated plasma  
ii) active TB and latent TB with 89% accuracy (90% sensitivity, 89% specificity)  
iii) latent TB and no TB in healthy controls with 77% accuracy (67% sensitivity, 84% 
specificity). 
Conclusions: 
SELDI-TOF MS proteomic profiles in combination with trained optimal classifiers 
accurately discriminate active TB from other respiratory disorders. The classifier for 
latent TB was not as accurate, but active TB could be discriminated from latent TB.  
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7 INTRODUCTION 
7.1 Tuberculosis 
Tuberculosis (TB) is an infectious disease caused by the organism Mycobacterium 
tuberculosis (MTB). In 2006 there were an estimated 9.2 million new cases of (TB) in 
the world, with an estimated 1.7 million deaths.[1] Multi-drug resistant cases (0.5 
million) and HIV co-infection (0.7 million) further complicate the global epidemic. 
[1, 2] New and undiagnosed cases drive the epidemic, with transmission often 
occurring before the index case is diagnosed.[3] Rapid diagnosis and treatment are 
vital in the prevention of TB transmission. Among communicable diseases, 
tuberculosis is the second leading cause of death worldwide, after the Human 
Immunodeficiency Virus (HIV).[4] TB is a unique and complicated infectious disease 
largely due to a complex natural history of infection 
7.2  The Natural History of Tuberculosis Infection 
Tuberculosis transmission occurs through the inhalation of droplet nuclei from 
respiratory secretions (aerosol transmission from infected individuals with active 
TB).[5] Tubercle Bacilli enter via the respiratory tract. Induction of host immune 
responses results in either containment of infection (latent TB) or multiplication of the 
organism resulting in clinical disease (active TB). Clinical disease develops in 5-10% 
of infected individuals.[6] Active disease can develop later due to endogenous 
reactivation of latent infection or exogenous re-infection[7]. Primary disease is 
defined by convention as disease within “5 years of initial infection” endogenous or 
post primary disease is defined as “disease with onset 5 years after the initial infection 
or after the most recent re-infection”.[8] An untreated sputum smear positive patient 
may infect over 20 contacts during the natural history of the disease.[9] Two billion 
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people worldwide are infected with latent TB, an enormous reservoir of potential TB 
cases.[4]  
7.2.1 Clinical Presentation 
Pulmonary disease is the most important clinical manifestation of TB, and will be the 
primary focus of this thesis. Extrapulmonary disease represents about 20% of disease 
burden in HIV negative individuals and a higher proportion in HIV positive 
individuals [10]. Forms of extrapulmonary TB include: lymphatic, meningeal, 
pericardial, bone, genitourinary and disseminated TB resulting in simultaneous 
involvement of many organs either as a result of primary progressive disease or 
reactivation of latent infection.  
All patients with a persistent cough should be assessed for pulmonary TB. Cough may 
initially be dry, but subsequently as inflammation and necrosis progress cough can be 
purulent or blood stained (haemoptysis). Other symptoms include fever, night sweats, 
weight loss, shortness of breath, and chest pain.[11] Fever in TB is a constant feature 
regardless of the focus of infection, although observation of fever in patients can vary 
from 37-80%, [12, 13] in one study 21% of patients had no fever at all during an 
inpatient stay with TB [12]. 
TB is a heterogeneous disease with many host and pathogen related factors 
contributing to the clinical presentation of disease. Age[14], immune status[15], 
malnutrition[16], genetic factors[17] and co-existing disease are among the most 
prominent host factors. Virulence of the organism is the most important pathogen 
related factor.[18] 
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7.2.2 Immunology of Host Pathogen Interaction 
MTB immune response is multi-faceted and complex. MTB enters alveolar 
macrophages and replicates, macrophages release inflammatory cytokines and 
chemokines as signals of infection. Monocyte derived macrophages and dendritic 
cells migrate to the site of infection. Dendritic cells then migrate to regional lymph 
nodes where CD4 and CD8 cells are primed against mycobacterial antigens. Primed T 
cells return to the lungs and site of infection. The migration of macrophages, T cells 
and B cells result in the formation of a granuloma (other cells in the granuloma 
include dendritic cells, endothelial cells, fibroblasts, and stromal cells).[19] Thus 
bacilli engulfed by macrophages are walled off from the rest of the lungs, limiting 
spread. In this way the host controls MTB but does not eliminate the pathogen from 
the body, with the possibility of subsequent re-activation. Autopsy studies confirm the 
presence of viable bacteria in latent TB individuals.[20] 
If T cell response is not enough to control infection, clinical symptoms develop 
resulting in active TB and a potentially infectious patient. Where the T cell response 
controls infection, there are no clinical symptoms and the individual is non infectious 
with latent TB.[21] 
Interferon-γ (IFN-γ) and Tumour necrosis factor (TNF)[22] play important roles in the 
orchestration of the immune response to TB. IFN-γ knockout mice are susceptible to 
TB[23], while human genetic mutations resulting in IFN-γ signalling deficiencies 
increase the susceptibility to TB.[24] 
The host-pathogen interaction is not one-sided. MTB can modulate the expression of 
major histocompatability molecules (MHC class II) and so limit antigen presentation 
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to the immune system.[25] MTB can also evade other components of the immune 
system by avoiding the effects of nitric oxide (NO) and RNI’s (reactive nitrogen 
intermediates).[26] MTB gene expression is altered to allow intracellular survival 
including expression of the dormancy DosR regulon [27]. These molecules allow a 
long term latent infection to be established so that MTB ensures it remains viable 
within the host.  
Diagnostic tests for active TB can be based around detection of the pathogen or the 
host response to the pathogen. Tests for latent TB are primarily based around the host 
response to the pathogen. 
7.3   Active TB Diagnostics – Pathogen detection 
7.3.1 Smear Microscopy 
Smear microscopy relies on the property of MTB to resist decolourisation during the 
staining process and remain acid fast. Ziehl-Neelson is the most commonly used stain. 
Sputum microscopy is simple, fast and requires few resources. Smears also give a 
quantitative estimation of the number of bacilli being secreted, giving important 
epidemiological information about the contagious state of a patient. 
Smear microscopy however has poor sensitivity for paucibacillary disease and 
requires between 5,000 and 10,000 organisms/ml of specimen to allow detection [28]. 
Sensitivity based on a single sputum smear can be <50%[29], requiring multiple 
patient visits to improve diagnosis. Sensitivity of sputum smear microscopy is also 
dependent on staining technique, centrifugation speed, reader experience and the 
prevalence of TB in the population. Smear negativity is greater in HIV positive 
individuals with TB than in HIV negative.[30] 
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The effects of sputum processing with centrifugation, and chemical pre-processing 
(Bleach and NaOH) result in an 18% increase in sensitivity (95% CI 11-26%). 
Gravity sedimentation with a chemical agent, usually bleach or ammonium sulphate, 
results in a 23% increase in sensitivity if sedimentation is overnight or a 9% increase 
if sedimentation is over shorter periods. There is a 12 % increase in sensitivity in 
using fluorescence microscopy.[31, 32] 
Despite poor sensitivity, 95% of TB cases and 98% of TB deaths are in low-middle 
income countries[1] and in these countries sputum microscopy is still the most 
important diagnostic test for active TB.  
7.3.2 Culture Methods 
The growth of MTB on solid culture medium either egg based Lowenstein-Jensen 
medium or agar based Middlebrook 7H10 / 7H11 remains a mainstay of TB 
diagnostics. The additional advantage of culture methods is that they can detect as few 
as 10 organisms/ml of specimen,[33] give information on drug susceptibility of the 
organism as well as genotypic information vital for epidemiology studies. Culture 
techniques have a sensitivity of 80-85% and a specificity of 98% [34, 35]. The biggest 
disadvantage of culture techniques is that MTB is a slow growing bacterium and so 
can take up to 6 weeks to be detected on a culture plate.[36] 
Growth in liquid medium (Middlebrook 7H12) occurs within 7-21 days. Commercial 
broth systems have utilised this rapid growth in liquid medium along with radiometric 
or calorimetric detection to produce automated mycobacterial detection systems such 
as BACTEC 460 (Becton Dickinson), mycobacterial growth indicator tubes (MGIT) 
and BacT/ALERT MB susceptibility kits.[37] These techniques require sophisticated 
equipment and a skilled workforce. The Microscopic-Observation Drug Susceptibility 
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assay (MODS) is a liquid medium based technique which detects the characteristic 
growth of MTB in liquid medium using an inverted light microscope. MODS has 
been shown to reduce the time to culture positivity (7days) and improve the sensitivity 
of TB detection (98%) compared to conventional Lowenstein-Jenson culture 
(84%).[38] 
7.3.3 Nucleic Acid Amplification Techniques (NAAT) 
Nucleic acid amplification techniques such as PCR can be used directly on sputum 
and other clinical specimens. PCR identifies MTB DNA, the most commonly used 
target in the MTB genome is the insertion sequence IS6110. The Sensitivity and 
Specificity ranges are <80% and 80-100% respectively. NAAT are most reliable in 
sputum smear positive cases where they provide a sensitivity of 95% and specificity 
of 98%.[39, 40]  In smear negative cases however the sensitivity is 48% with a 
specificity of 98%. Contamination of equipment and samples can result in false 
positive results.[41] 
7.3.4 Phage Based Diagnostics 
Mycobacteriophages are viruses which specifically infect live MTB. When coupled 
with a fire-fly luciferase gene, phages can be used to detect the presence of MTB in 
sputum.[42, 43] Data from a meta-analysis suggest that phage based diagnostics have 
a sensitivity of 21-88% and a specificity of 83-100%.[44] Overall the conclusion was 
that although phage assays give results similar to smear microscopy they are more 
complex and resource intensive.  
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Drug resistance can be diagnosed using phage based assays, when MTB is detected in 
samples containing the drug. Sensitivity and specificity estimates have been as high as 
95% when performed on culture isolates.[45]  
Despite many promising molecular techniques for the detection of mycobacterium in 
sputum, none are accurate enough to replace smear microscopy and culture 
techniques. 
7.4 Active TB Diagnostics – Host response 
7.4.1 Serodiagnostics 
Serological tests have successfully been developed for a large number of infectious 
diseases such as malaria[46], HIV[47] and influenza[48], providing point-of-care 
rapid and inexpensive bed side tests. Multiple attempts to develop serodiagnostic tests 
for TB have been unsuccessful. The humoral immune response to MTB is highly 
heterogeneous and dependent on the different stages of disease, bacillary load, HLA 
types and the immunocompetency of the host.[49] 
Davidow et al investigated serum antibody levels to 6 MTB antigens grouped into 4 
diagnostic categories (active disease, past disease, latent disease and infection 
free).[50] Antibodies to the 38kDa antigen, alanine dehydrogenase and Rv2626c were 
associated with active disease, while antibodies to the 16kDa antigen, ferredoxin A 
and ESAT-6 were associated with inactive TB. Other studies have shown antibodies 
to Heat Shock Protein (HSP) 71[51] to be increased in sputum smear negative 
pulmonary disease, antibodies to the 16kDa antigen to be increased in chronic 
household contacts of TB patients[52] and antibodies to lipoarabinomannan (LAM) to 
be raised in the CSF (cerebrospinal fluid) of patients with TB meningitis.[53] The 
potential use of serodiagnostic markers in TB is however complicated by issues of TB 
and HIV co-infection. 
21 
 
In a systematic review Steingart et al concluded that none of the commercial 
serological tests for TB performed well enough to replace smear microscopy.[54] 68 
studies were considered with sensitivity ranging from 10% to 90% and specificity 
from 47% to 100%. Specificity was higher in healthy controls than in clinically 
relevant unhealthy controls suspected of having pulmonary tuberculosis. Antibody 
tests can not distinguish current disease from past disease. 
Tuberculostearic acid as a biomarker has been investigated in the diagnosis of 
pulmonary and cerebral tuberculosis, through its detection in femtomole quantities by 
gas-liquid chromatography.[55] However, lack of specificity results in many false 
positives and gas-liquid chromatography is not available in peripheral clinical 
laboratories.  
7.4.2 Tuberculin Skin Test (TST) 
Since the early 1890’s the intradermal administration of tuberculin has been used as a 
diagnostic test for tuberculosis infection. Tuberculins are extracts of culture filtrate 
and contain antigenic components of TB which when injected under the skin produce 
a delayed-type hypersensitivity reaction. In an individual with TB infection, sensitized 
T-cells are recruited to the skin site, release lymphokines and produce the resulting 
induration through the recruitment of an inflammatory reaction. The size of induration 
measured in mm determines a positive test result.[11, 56] 
Tuberculin is not specific to MTB, the TST therefore does not discriminate TB from 
Mycobacteria other than TB (MOTT) or BCG vaccination. The TST also fails to 
discriminate active TB from latent TB as the immune system is sensitised to TB 
antigens in both disease states.[57, 58] 
Overall the TST is of limited value in the diagnosis of active TB, not only because of 
false positives, but also due to false negatives as a result of immune anergy in states of 
malnutrition, old age and immunodeficiency [59, 60]. It is still however used on 
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occasions to aid the diagnosis of TB, assuming conditions causing anergy are not 
present a negative result would not support the diagnosis. 
7.4.3 Interferon Gamma Release Assays 
Whole blood interferon-γ release assays (IGRA) detect cell mediated immunity to TB 
specific antigens. Commercial diagnostic tests based on the secretion of interferon 
gamma in response to MTB specific antigens are now licensed.[61, 62]  The two most 
notable tests available are the QuantiFERON-TB Gold (Cellestis Ltd) and the Enzyme 
linked immunospot assay (Elispot) which have both been extensively studied.[63-68]  
The Quantiferon (QFN) assay uses ELISA to measure antigen specific production of 
IFN-γ in whole blood, while the Elispot uses Peripheral blood mononuclear cells 
(PBMC) from whole blood and visualises sensitised cells. Both tests rely on MTB 
specific antigens produced from the region of difference (RD1) in the MTB genome 
which is not present in BCG or Mycobacterium avium complex (MAC). These 
antigens include: Early secretory antigenic target-6 (ESAT-6), Culture filtrate protein-
10 (CFP-10) and TB-7.7.[69] 
Studies in the role of IGRAs to diagnose active TB have concluded that although the 
specificity is markedly increased compared to the TST, the sensitivity in active TB is 
still suboptimal compared to culture methods.[70]  In one meta-analysis the pooled 
sensitivity for QFN assay was 76%, Elispot 88% and the TST 71%.[71] It is felt that 
in part, this suboptimal response may be due to diminished Cell Mediated Immunity 
(CMI) in active TB. In one case report however, Lalvani et al report the use of the 
Elispot assay in diagnosing subclinical active TB in an immunosuppressed patient 
with a false negative TST. [72] 
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IGRAs like the TST and any test assessing CMI to TB can not distinguish active TB 
from past or latent TB; this has confined their use primarily as a tool in the diagnosis 
of latent TB. 
7.5 Latent TB Diagnostics 
7.5.1 Tuberculin Skin Test (TST) 
First described by Robert Koch in 1890, for many years the TST has been the only 
test available for latent TB. Study of accuracy is limited as we have no gold standard 
investigation for latency and are dependent on surrogates such as active TB and past 
history of TB which may not accurately depict the immune status of an individual 
with latent TB. 
As discussed previously the TST has many limitations including false positives from 
BCG vaccination and MOTT and false negatives from medical anergy. The TST also 
requires 2 patient visits and there is considerable potential for subjectivity with 
administration and reading results.  
The response to the TST wanes as an individual gets older and assessment of latent 
TB status is complicated further by the booster effect, whereby an initial test may be 
negative but a subsequent test performed within a year becomes positive. The booster 
effect may suggest an individual has been infected in the last year when in reality it 
reflects an anamnestic immune response to previous infection.[73] 
Many different criteria also exist for the cut off value for a positive TST: 10mm 
accepted for most individuals, 15mm in some countries for BCG vaccinated 
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individuals and 5mm for the immunosuppressed patients. The ideal cut off value for a 
population will be dependent on the prevalence of TB in that community.[74-76] 
Despite its limitations the TST has played an important role in the diagnosis of latent 
TB and has only recently been challenged by the development of IGRAs. 
7.5.2 Interferon-γ Release Assays 
The new generation of latent TB tests based on the expression of IFN-γ in response to 
specific antigens from MTB has changed our approach to the diagnosis of latent TB. 
The tests have several advantages over the TST: they are more specific, only require a 
single patient visit, simultaneously measure host immune reactivity to mitogen and 
provide a less subjective result within 24 hours.[68] The main disadvantages are cost 
and laboratory expertise.  
7.5.3 Limitations of latent TB investigations 
The lack of a gold standard diagnostic test for latent TB limits our assessment of 
IGRAs and the TST. In order to confirm the existence of latent TB one would need to 
follow an individual in a longitudinal study to see whether they subsequently develop 
active TB, or conduct an autopsy study at the time of death, neither of which is 
practical. 
No diagnostic test for latent TB will discriminate between active TB or past TB; any 
test based on CMI does not give an indication of the timing of infection.  
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7.6 Tuberculosis diagnostics - pattern recognition 
7.6.1 Pattern recognition and Supervised Machine Learning 
Recent years have seen an increase in the diagnostic paradigm of identifying disease 
through pattern recognition analysis. The host and pathogen in TB lend themselves to 
the extraction of large amounts of complex biological data at a molecular and clinical 
level. Bioinformatics and machine learning techniques are used to extract useful 
knowledge from these large data files and identify patterns which could potentially be 
used for diagnostic purposes. 
In Supervised machine learning (SML) computers are programmed to optimise a 
performance task by using example data or past experience. SML induces 
classification rules from labelled examples of data and then uses these rules to classify 
unlabelled data. Examples of machine learning modalities include neural networks, 
genetic algorithms and support vector machines (SVM).[77] 
SVMs transform data (using kernel functions) and represent them mathematically in a 
higher dimensional space, where the 2 classes can be separated by a hyperplane.  The 
goal of support vector machines is to find the separating hyperplane with the largest 
margin. By learning to separate data in this way the SVM can find discriminatory 
patterns in complex datasets. 
7.6.2 Tuberculosis and pattern recognition 
Pattern recognition and machine learning algorithms have been used in many TB 
diagnostic and epidemiological studies. Microarray studies use pattern recognition 
technology to observe differences in gene expression identified on a multiplex lab-on-
a-chip. Oligonucleotides representing every gene in a genome are coated onto a glass 
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slide at high density; these capture complementary sequences in a target solution and 
give information about gene abundance in the solution. Whole genome microarrays 
for MTB were first described by Schoolnik et al [61] in 1999, since when microarrays 
have been used to assess the gene expression response of MTB to a variety of stresses 
including hypoxia [78], heat shock  and acidic conditions [79]. This has allowed a 
valuable insight into the differential expression of genes important in the host 
pathogen interaction.[80] 
Spoligotyping is a method based on polymerase chain reaction (PCR) amplification of 
a highly polymorphic direct repeat locus in the MTB genome. This technique allows 
the differentiation of various isolates of MTB. Large amounts of data are generated 
and supervised and unsupervised methods of machine learning have been used to 
classify the data[81] 
Volatile organic compounds in breath produced by MTB and the oxidative stress of 
infection have been detected by gas chromatography / mass spectrometry. Pattern 
recognition analysis has been used to distinguish healthy controls from active TB 
cases with 100% sensitivity and 100% specificity.[82] Different species of 
mycobacterium have been identified using high performance liquid chromatography 
and fluorescent detection of mycolic acids (HPLC-FL) combined with pattern 
recognition algorithms. This technique detected MTB and MAC (mycobacterium 
avium complex) in 1 day from smear positive sputa.[83] Computer driven pattern 
recognition models have also been used to detect abnormalities related to TB in chest 
radiographs.[84] 
The pattern of circulating proteins identified by Mass Spectrometry (MS) was recently 
used to discriminate active TB patients from controls using SVM classifiers. Agranoff 
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et al defined the importance of pattern recognition in the plasma proteome in TB, 
achieving a diagnostic accuracy of 94% (sensitivity 93.5%, specificity 94.9%).[85] 
Advances in proteomics and SML have opened the doors to exploring the plasma 
proteome further in a bid to find new diagnostic tests for TB. An understanding is 
required of the complexity of the plasma proteome and the many ways in which it can 
be explored. 
7.7 Proteomics 
7.7.1 The Plasma proteome 
The selection of proteins present in a complex biological solution is referred to as the 
proteome. The human plasma proteome is a complex, accessible and constantly 
changing reflection of the body. Where the genome represents the genotype of an 
individual the proteome represents the phenotypic state of the body in a single 
moment of time.  
The proteome consists of plasma proteins, hormone messengers, and distinct 
immunoglobulins. In a disease state plasma also contains tissue leakage proteins, 
released as a result of cell damage and death. Disease specific tissue leakage proteins 
represent valuable diagnostic biomarkers. A prominent example of this is the release 
of cardiac specific troponin in an acute mycocardial infarction as a result of minimal 
myocardial damage.[86, 87] 
Infectious diseases are associated with alterations in circulating proteins of host or 
pathogen origin.[88] Any disease has a defining and possibly unique set of proteins (a 
‘proteomic profile’) and in combination these markers have strong discriminatory 
power. In a disease like TB where the host pathogen interaction is different in the 
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active and latent phase, study of the plasma proteome could give valuable new 
diagnostic opportunities as demonstrated by Agranoff et al. 
7.7.2 Dynamic range of the plasma proteome 
Plasma is a difficult proteome to characterise as it contains such a large dynamic 
range. 55% of plasma is made up of albumin present at a concentration of 35-
50mg/ml. Cytokines such as IL-6 are present in a concentration range of 0-5pg/ml, 
resulting in a difference of a factor of 1010 between the 2 proteins. To put this into 
context finding 1 molecule of an analyte present at 10pg/ml among albumin 
molecules present at 55mg/ml is like finding 1 human being in the entire population 
of the world. A small number of proteins dominate the plasma protein concentration 
with the vast majority of proteins only forming 1% of the total concentration.[87] 
The Human Proteome Organization (HUPO) has played a very important role in not 
only identifying proteins but also establishing standardised methods and reliable 
databases for the investigation of the plasma proteome.[89] 
7.7.3 Plasma pre-analytical techniques 
Large abundance proteins such as albumin, transferrin and immunoglobulin can be 
removed from the plasma to allow the analysis of the low abundance proteins which 
are potentially more disease specific. Two major types of depletion method have been 
used to remove abundant proteins from plasma; one based on the dye Cibacron Blue 
F3GA which when bound to agarose removes albumin from complex solutions, the 
other dependent on antibody depletion using chicken yolk IgY columns. The Cibacron 
blue technique is not specific to albumin and will remove other potentially important 
proteins with an isoelectric point similar to albumin. In one study using IgY columns 
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coupled with specific antibodies to 7 abundant rat plasma proteins (IgY-R7-LC2, 
Beckman Coulter), the column was shown efficiently to remove most of the abundant 
proteins. [90] The depletion process however resulted in significant dilution of the 
original sample and so only a few new low abundant proteins were identified.  
Although these techniques reduce the dynamic range of plasma by 2-3 orders of 
magnitude, there is still a difference of 7-8 orders of magnitude between medium 
abundance and low abundance proteins.  
Anion exchange fractionation of plasma using commercial kits relies on binding 
proteins at high pH to Q Ceramic HyperD® resin and sequentially eluting the proteins 
with solutions of progressively lower pH and an organic solution. In this way the 
complexity of plasma is reduced into many smaller fractions each containing proteins 
with similar isoelectric points. This pre-fractionation technique allows the detection of 
low abundance proteins which would otherwise have been masked by higher 
abundance proteins. Coupled with mass spectrometry many investigators have used 
this technique in biomarker discovery studies. In a study comparing albumin depletion 
methods with anion exchange pre-fractionation Ziad et al found that the clinically 
relevant plasma protein prostate specific antigen (PSA) was lost along with albumin 
depletion but was still detectable using the anion exchange method.[91] 
A novel approach to the pre-analytical process involves the use of commercially 
available ProteoMiner™ protein enrichment kits. This technology enriches and 
concentrates proteins of low abundance while still retaining high abundance proteins 
at acceptable concentrations. This is achieved through the use of short peptide 
fragments as affinity recognition sites, in libraries which contain all possible amino 
acid sequences. High abundance proteins will saturate their binding sites and excess 
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protein will be removed by washing the beads, leaving a diverse selection of proteins 
bound to the beads for analysis. [92, 93] 
7.7.4 Two Dimensional (2D) gel electrophoresis 
2D gel electrophoresis allows the separation of proteins in biological solution by 
isoelectric point (pI), as well as molecular weight on SDS-polyacrylamide gels. The 
technique is inexpensive, covers a large mass range and is able to resolve up to 1000 
proteins. The study of plasma proteins by 2D gel electrophoresis was first conducted 
by Anderson et al [94] resulting in the resolution of 300 spots, in 1991 727 spots were 
resolved and 49 different proteins identified.[95] One of the biggest advantages of 2D 
gel studies on plasma has been the detection of post-translational modifications of 
proteins – Haptoglobin, for example produces up to 43 resolved spots.[96] 
Disadvantages of 2D gel electrophoresis result from poor reproducibility secondary to 
gel to gel variation; running gels can be time consuming and technically challenging. 
2D gels do not cover proteins and peptides of low molecular weight (<30kDa). 
Proteins which are hydrophobic, strongly acidic or strongly basic are also very poorly 
resolved. Overall 2D gels provide moderate sensitivity and low throughput. 
Sensitivity has been improved by pre-fractionation and using fluorescently labelled 
proteins but this represents more time and cost.[97] 
Early proteomic studies in TB have compared the proteomic profiles of culture 
supernatants from different strains of MTB using 2D gel electrophoresis. Mattow et al 
compared virulent MTB H37Rv and attenuated Mycobacterium bovis BCG 
Copenhagen and identified 27 different proteins as potential antigens for novel 
vaccines and diagnostic tests. [98, 99] 
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7.7.5 Mass spectrometry 
Mass spectrometry (MS) determines the mass charge ratio (m/z) of gas phase ions 
generated most commonly by electrospray ionisation (ESI) or Matrix-assisted laser 
desorption/ionization (MALDI). In MALDI, analytes are mixed with photoreactive 
matrix molecules, dried on a metal surface and ionised with laser irradiation. Time of 
flight (TOF) describes the method used to measure the time that it takes for an ion to 
reach a detector when accelerated by an electric field; this time is dependent on the 
mass and the charge of the ion and so is used to calculate the m/z ratio. Smaller 
proteins are accelerated to higher velocities than heavier proteins and are thus 
detected earlier. MS, unlike 2D gels, can be applied to the study of naturally occurring 
peptides, peptide fragments derived from proteins and whole proteins.[100] 
7.7.6 Mass spectrometry: Bottom up  
In this approach proteins are digested with trypsin into peptides which are further 
fragmented with tandem mass spectrometry (MS/MS) to generate sequences of 
peptides which when combined with protein databases can lead to the identification of 
the protein. The technique when combined with fractionation reduces the complexity 
of the peptide mixture introduced into the MS. Multidimensional Protein 
Identification Technology (MudPIT) separates proteins in 2D liquid chromatography 
and can be interfaced with the ion source of a mass spectrometer allowing the 
separation and identification of complex protein and peptide mixtures. This technique 
has identified up to 1500 yeast proteins with a dynamic range of 4 orders of 
magnitude [101] and 490 proteins in human serum.[102, 103] The technology is 
effective at low molecular weight and for low abundance proteins and peptides in 
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complex solutions. The time, cost and throughput of the technique does limit its use in 
large scale biomarker discovery projects. 
7.7.7 Mass spectrometry: Top down  
Whole proteins can be analysed by MALDI-TOF and its variant Surface-enhanced 
laser desorption/ionization – Time of flight (SELDI-TOF). Aluminium based arrays 
are chromatographically modified to bind to proteins with particular chemical 
properties, while non-bound proteins are removed by washing. Common surfaces 
include CM10 (weak cation exchange), H50 (Hydrophobic, reverse phase 
chromatography), IMAC30 (metal-binding surface) and Q10 (strong anion exchange). 
Pilot studies are conducted to compare patients with controls using a variety of chip 
surfaces in different biochemical conditions; the surface which yields the greatest 
discrimination between the 2 groups is then used to conduct large scale studies.[104, 
105] 
SELDI-TOF combines solid chromatography separation with mass spectrometry to 
produce a sensitive, high throughput platform ideal for biomarker discovery.  
7.8 SELDI-TOF 
7.8.1 SELDI-TOF and biomarker discovery  
Exploration of potential biomarkers for TB has been considerably improved with 
advances in Proteomic profiling technology.  Infectious diseases are associated with 
alterations in circulating proteins of host or pathogen origin.[88] Any disease has a 
defining and possibly unique set of proteins (a ‘proteomic profile’) and in 
combination these markers have strong discriminatory power. By generating profiles 
from cases and controls, supervised machine learning algorithms can be used to 
identify discriminatory patterns and from these potential disease biomarkers. 
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This new approach to diagnostics was first applied to the diagnosis of cancer[106-
108] and its applicability to infectious diseases has also been demonstrated [109]. The 
system can in principle detect proteomic patterns reflecting the host-pathogen 
interaction i.e. the disease state, rather than merely the presence of the pathogen. In a 
disease like TB where the distinction between infection and overt disease has 
important clinical implications, different clinical manifestations could be associated 
with distinctive proteomic signatures. 
7.8.2 SELDI-TOF: criticisms 
Concerns have been raised about the use of proteomic profiling as a novel diagnostic 
technology. Particular attention has been drawn to the idea that differences seen 
amongst spectra may not represent true biological differences but might represent 
artefacts in sample collection, processing and storage.[110] Attention has also been 
directed at lack of comparability of generated datasets and poor reproducibility over 
multiple experiments.[111] 
The issue of analytical and biological bias is important in these experiments as has 
been seen with some studies where bias contributed to the study outcome.[112, 113] 
Bias is amplified by the highly sensitive nature of mass spectrometry. Differences in 
collection sites can result in greater spectral differences than biological differences do 
between samples. [114] 
These criticisms in turn have resulted in an extensive literature addressing issues of 
quality control of SELDI-TOF experiments and standardisation of sample 
collection.[115] Large multi-centre studies have dispelled some of these concerns 
[116].Analysis requiring consistency in sample handling and standardised protocols 
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has been helped considerably by automating the process. Quality control must be 
central to any SELDI-TOF study. 
SELDI-TOF analysis and the use of a SVM was the platform that was used by 
Agranoff et al to discover discriminatory patterns in the plasma proteome of TB 
patients.[85] The focus of this thesis will be a follow on study from this original work. 
7.9 Hypothesis and Aims 
Advances in mass spectrometry and supervised machine learning allow the sensitive 
and high throughput analysis of the plasma proteome in different disease states. 
The primary hypothesis of this thesis is that differences in the host pathogen 
interaction will define distinct plasma proteomic profiles in active and latent TB. 
These profiles will be able to discriminate active TB from unhealthy individuals with 
symptoms similar to TB. Profiles will also be able to distinguish individuals with 
latent TB from those with the absence of TB or with active TB. Potential biomarkers 
of active TB and latent TB could be derived from these discriminatory profiles. 
The study will recruit individuals from an appropriate population and categorise them 
appropriately into the diagnostics groups that will allow the above hypothesis to be 
tested: active TB, unhealthy controls with symptoms similar to TB, latent TB and the 
absence of TB. By collecting clinical, laboratory and epidemiological data from study 
participants the aim will be to accurately define the different disease states. For latent 
TB where no gold standard investigation exists a further aim will be to evaluate 
currently available diagnostic tests for latent TB with a view to defining latent TB 
accurately in this population. 
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Proteomic profiles will be generated using SELDI-TOF technology from the plasma 
samples. In order to minimise analytical bias and ensure only high quality data is 
analysed, QC measures and standardisation of all protocols will remain a focused aim 
throughout the project. Machine learning algorithms as well as standard statistical 
techniques will be used to discover discriminatory patterns which distinguish the 
various diagnostic groups and interrogated to provide candidate disease biomarkers.  
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8 METHODS 
8.1 Study Participants 
8.1.1 Setting 
All participants were recruited from a shanty town in Northern Lima, Peru. Ventanilla 
has a population of 400,000 people with approximately 400 new cases of tuberculosis 
each year. Based upon government statistics, approximately 95-98% of TB patients 
are believed to be HIV negative, although HIV tests were not performed for this 
research. 
Cases of TB were identified through positive sputum microscopy from 15 health posts 
in the region.  
Over different periods of time from June 2003 to November 2007 TB patients, their 
household contacts, unhealthy controls with symptoms suggestive of TB and 
community healthy controls were recruited from this community. 
8.1.2 Study participants 
All participants below the age of 15 were excluded because household contacts of TB 
patients under 15 receive TB prophylactic treatment under local guidelines.  
Active TB cases were recruited on the basis of positive sputum microscopy. Where 
possible and in the majority of cases, patients were recruited and plasma samples 
taken before TB treatment had been initiated otherwise plasma was taken within 1-2 
days of treatment. Unhealthy controls with subsequent confirmation of TB through 
sputum microscopy or sputum culture were also analysed in this group. TB patients 
had bloods performed for proteomic studies and IFN-γ assay but did not receive a 
TST (Tuberculin Skin Test). 
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Household contacts of TB patients were recruited from June 2003 to May 2006. 
Household contacts had a TST performed throughout this period and those recruited 
from March 2005 also had an IFN-γ assay performed. Household contacts with 
symptoms suggestive of TB and later confirmation of the absence of TB were 
recruited as unhealthy Controls for the proteomic study. 
Unhealthy controls were in the majority of cases recruited from one of the health post 
clinics exclusively set up for TB screening. Individuals were recruited if they had a 
persistent cough and 2 or more of the following constitutional symptoms: fever, 
weight loss, decreased appetite or haemoptysis. In this way clinically relevant control 
samples were recruited. All unhealthy controls had sputum smear and culture analysis 
to exclude pulmonary TB and were reviewed 6 months to 1 year after recruitment to 
exclude TB.  
Healthy controls were recruited from randomly selected households in the 
community. These households did not have active TB patients resident and 
proportionately covered the same geographical distribution as TB households. 
Healthy controls had bloods performed for proteomic studies and IFN-γ assay as well 
as a TST. 
All participants gave written informed consent and the research was approved by 
ethics committees at Universidad Peruano Cayetano Heredia (UPCH), Prisma and 
Imperial College London. 
8.2 Sample Collection and Processing 
8.2.1 Sample and clinical data collection 
Each participant completed a questionnaire giving information on demographics, 
socio-economic status, TB exposure, BCG vaccination and symptoms.  
Individuals were invited to give a 20 ml blood sample which was immediately divided 
into 5 tubes: an EDTA-anticoagulated plasma tube (4ml), serum tube (7 ml) and 3 
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tubes for the IFN-γ assay (Quantiferon-gold) to assess latent TB status. A tuberculin 
skin test (TST) was also performed on all participants except those known to have 
active Tuberculosis. (5 units of PPD in 0.1 ml were injected intradermally and 
induration read 48 hours later).  
All participants had a weight, height and the following anthropometric measurements 
taken: Mid arm circumference (MAC), Triceps skinfold thickness (TSF), Biceps 
skinfold thickness, Subscapular skinfold thickness and iliac skinfold thickness. 
Corrected Arm Muscle Area (CAMA) was calculated using the following formulas: 
Male CAMA = [ (MAC – π x TSF)2 / 4π  ] – 10 
Female CAMA = [ (MAC – π x TSF)2 / 4π  ] – 6.5 
Field work was conducted by a team of 8 research nurses with involvement of the 
PhD candidate (from October 2005) in organisation of standardised collection of 
samples and recruitment of unhealthy controls from the health post clinic.  
8.2.2 Sample processing  
The time of blood collection was recorded on tubes and tubes were processed 6 hours 
after initial collection in the field.  
A capillary haematocrit was performed on each sample to give haemoglobin 
estimation. Serum and Plasma samples were centrifuged at 3500 rpm for 10 minutes 
before being divided into 100µl aliquots and immediately frozen at -700C.  
The cells left over from the plasma tube were re-suspended with 2ml Phosphate 
Buffered Saline (PBS pH 6.8) and carefully placed above a 4ml column of ficcoll in a 
10ml falcon tube. Tubes were centrifuged for 30 minutes at 400g and Peripheral 
Blood Mononuclear Cells (PBMCs) isolated using a transfer pipette. 
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After 2 wash cycles with PBS, cells were lysed with 500µl lysis buffer (50mM Tris 
HCl, 0.3M KCl, 2% Triton-X 100, 1mM EDTA and 1mM PMSF). Phenyl-methyl-
sulphonyl-fluoride (PMSF) was used as a protease inhibitor and was added fresh to 
the lysis buffer at the time of lysis. Tubes were further centrifuged to remove cellular 
debris and the lysate was frozen and stored in 100µl aliquots at -700C. 
8.2.3 IFN-γ assay : The QuantiFERON® -TB Gold in tube assay 
The QuantiFERON®-TB Gold in tube assay (Cellestis) was used. Three 1ml 
heparinised blood tubes: a negative control, a positive control containing the T-cell 
mitogen phytohaemagglutinin and a third tube containing ESAT-6, CFP-10 and TB 
7.7 TB specific antigens were incubated at 370C for 16-22 hours. Tubes were 
centrifuged at 3500 g, plasma harvested and stored at -200C until batch ELISA tests 
were performed at subsequent dates according to the manufacturer’s guidelines. 
Where an optical density fell outside the range of the ELISA plate reader a 1 in 100 
dilution was performed and actual IFN-γ concentration calculated. 
8.2.4 Statistical analysis 
Using data collected on the TST and IFN-γ assays from June 2003 to November 2007 
a statistical analysis was performed to determine the most appropriate test to use to 
define latent TB in this community. 
Statistical analysis was performed using STATA version 10 (Stata Corp, College 
Station, Texas). The primary outcome measure was the difference in prevalence of 
latent TB infection according to both tests. Levels of concordance between TST and 
IFN-γ assay were calculated using 2x2 contingency tables. Strength of agreement was 
assessed using Cohen’s Kappa (κ) statistic. (κ > 0.75 excellent agreement beyond 
chance, κ 0.4-0.75 fair to good agreement beyond chance and κ <0.4 poor agreement 
beyond chance). Multivariate logistic regression models were used to identify 
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variables associated with a positive result for each test, and factors associated with 
discordance. 
8.3 SELDI-TOF studies 
8.3.1 Quality control sample 
Blood was collected in 4 EDTA tubes from a healthy volunteer and centrifuged at 
3500rpm for 8 minutes. Plasma was harvested and aliquoted into 30-50µl aliquots 
which were immediately stored at -800C. This Quality control sample was 
subsequently used in all SELDI- TOF experiments. 
8.3.2 Sample Transport and Experiment design 
Plasma and PBMC samples were transferred to the UK from Peru with dry ice using a 
commercial courier service (World Courier Management Inc.). All samples underwent 
one freeze-thaw cycle prior to analysis. Samples from TB patients and controls were 
coded and analysed blind, randomly distributed on the same chips to reduce bias. All 
samples were run in duplicate with 1 quality control sample on each chip at random 
spot positions. Bio-Rad weak cation exchange chips (CM10) were used for plasma 
samples. Plasma samples from active TB patients were processed with samples from 
unhealthy controls to form the active TB discriminatory analysis. These samples were 
processed as fractionated as well as crude plasma.  
Plasma and PBMC samples from healthy controls were processed together to form the 
latent TB discriminatory analysis. These samples were processed crude and not 
fractionated. All samples to be compared within one experiment were run within 1-2 
days of each other.  
8.3.3 Instrument reproducibility 
Instrument reproducibility was assessed by using the ProteinChip® System Check Kit 
(Bio-rad) every time a new set of experiments was to be conducted. This involved 2 
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maintenance procedures: detector calibration (adjusts the detector voltage to improve 
reproducibility) and high voltage conditioning (to decontaminate the surfaces of the 
instrument). The kit also has 2 test procedures using pre-prepared protein chips. 
Detector sensitivity was assessed by measuring the signal/noise of IgG at 2 different 
concentrations 10 fmol and 140 fmol. Mass drift and resolution were assessed by 
measurements made on insulin, all measurements were compared to a specification 
and a pass/fail result obtained for each test. During the course of spectra acquisition 
the System Check Kit was run every 4 weeks. 
8.3.4 Instrument Calibration 
Instrument calibration was performed using All-in-1-peptide calibrant in the low mass 
range and All-in-1-protein calibrant(Bio-rad) in the high mass range. Specific 
calibrants used were [Arg8]-Vasopressin (1084.2), Human ACTH [1-24](2933.5), 
Human recombinant Insulin(5807.7), Bovine Cytochrome C(12,230), Equine Cardiac 
Myoglobin(16,952), Bovine RBC Carbonic Anhydrase(29,024) and S.cerevisiae 
Enolase(46,671).  Instrument calibration was performed before generating each set of 
spectra and the most recent calibration equation applied.  
8.3.5  CM10 anion exchange chip sample preparation 
All buffers were prepared in bulk, aliquoted and stored at -200C. The same batch of 
buffers was used to analyse all samples compared within one experiment. Samples 
were thawed on ice, centrifuged at 13,000rpm for 2 minutes and diluted in 
denaturation buffer 1:10 (9M urea, 2% CHAPS, 2mM DTT, pH 9.0). Samples were 
left to denature on ice for 30 minutes.  
All subsequent liquid handling steps were automated and performed on a Biomek 
3000 Laboratory Automation Workstation (Beckman Coulter) using a 96 well 
Bioprocessor configured to accommodate 12 SELDI chips. 
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Weak Cation exchange CM10 chips were equilibrated with 150µl of binding Buffer 
(100mM Ammonium Acetate pH 4.0, 1% Triton X-100, pH 4.0) on the Bio-mek 
Micro-mix plate for 5 minutes. A further 10 fold dilution of the denatured plasma 
sample was performed with binding buffer to apply samples to the appropriate well of 
a 96 well plate (90µl Binding buffer 10µl sample). The Bioprocessor was centrifuged 
at 1000rpm for 1minute, covered with adhesive film and incubated for 1 hour at room 
temperature on the micro-mix plate (amplitude 7, form 20). 
After incubation wells were washed, decanted and blotted 3 times with Binding 
Buffer, 2 times with Wash Buffer (100 mM Ammonium Acetate pH 4.0) and once 
with distilled water. The Bioprocessor was inverted over a paper towel and 
centrifuged for 1 min to dry the chips.  
A saturated solution of Sinapinic Acid (SPA) was prepared in a light proof eppendorf 
by adding 600µl Acetonitrile and 600µl 1% Trifluoracetic acid (TFA) to 40mg of 
SPA. The solution was vortexed for 10 minutes and centrifuged for a further 10 
minutes at 13000 rpm. A 50% saturated SPA solution was then prepared by 
transferring 1 ml of the saturated solution and adding 500µl  of acetonitrile and 500µl  
of 1% TFA. 1µl of matrix was applied to each spot and allowed to dry for 5 minutes, 
this process was completed twice and chips allowed to air dry before being read on a 
System 4000 Bio-rad mass spectrometer. 
8.3.6 Plasma anion exchange fractionation 
Anion- exchange fractionation of plasma was conducted using the ProteinChip® 
Serum Fractionation Kit (Bio-rad), all liquid handling steps of the process were 
automated using a Biomek 3000 Laboratory Automation Workstation.  
Previously aliquoted and frozen Urea/Chaps (9M urea, 2% CHAPS, 2mM DTT, pH 
9.0) solution was thawed on ice, U1 solution was prepared from this by adding 12ml 
of Urea/Chaps to 96ml of rehydration buffer (50mM Tris-HCl, pH 9.0).  
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Plasma samples were thawed on ice and centrifuged at 13,000 rpm for 2 minutes. For 
each fractionation plate 30µl of 86 plasma samples along with 10 quality control 
samples were transferred to a 96-well plate and incubated with 45µl of urea/chaps 
solution for 20 minutes on ice. The Anion-exchange Q ceramic beads on the 
fractionation plate were equilibrated with 200µl of Rehydration Buffer for 60 minutes 
at room temperature on the Biomek Micro-mix plate (form 48, amplitude 7). The 
buffer was removed by placing the plate over a vacuum manifold and applying a 
vacuum of 15mmHg. The beads were then washed with 200µl of rehydration buffer 3 
times and with 200µl U1 buffer a further 3 times, with each wash the vacuum was 
applied to remove buffer.  
Once rehydration was complete, 50µl of sample in urea/chaps solution was transferred 
from the 96 well-plate to the corresponding well on the fractionation plate. 50µl of U1 
solution was added to each well of the fractionation plate. The plate was covered with 
adhesive sealing film and mixed on the Bio-mek Micro-Mix plate for 30 minutes 
(form 20, amplitude 7). 
96 well plates were labelled F1 through to F6 for each of the 6 fractions to be 
collected. The plate labelled F1 was placed underneath the filtration plate on the 
vacuum manifold and the flowthrough collected. 100µl of Wash Buffer 1 (50mM 
Tris-HCl, 0.1% OGP, pH 9.0) was then added to each well, the filtration plate mixed 
for 10 minutes on the Micro-Mix Plate (form 20, amplitude 7) and the eluate collected 
again into the F1 plate.  All subsequent fractions were collected in a similar manner 
washing twice with 100µl of the appropriate wash buffer, mixing for 10 minutes and 
collecting the eluent in the corresponding labelled 96-well plate. The following 
buffers were used for each fraction: Wash Buffer 2 (50 mM HEPES, 0.1% OGP, pH 
7.0), Wash Buffer 3 (100 mM Na acetate, 0.1% OGP, pH 5.0), Wash Buffer 4 (100 
mM Na acetate, 0.1% OGP, pH 4.0), Wash Buffer 5 (50 mM Na citrate, 0.1% OGP, 
pH 4.0) and Wash Buffer 6 Organic fraction (33.3% isopropanol, 16.7% acetonitrile, 
0.1% TFA). On completion the fraction plates were sealed and stored at -80 C. 
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8.3.7 Processing of fractions on CM10 chips 
Each fraction was processed in 1 day. The fraction plates were thawed on ice and 10µl 
transferred from the plate to 90µl of CM10 Binding Buffer in the Bioprocessor. The 
Bioprocessor was incubated for 1 hour and all subsequent steps were as described in 
section 8.3.5 above. 
8.3.8 Optimisation and spectra generation 
Data collection settings were optimised in Manual Mode on the mass spectrometer by 
varying the laser energy and mass focus and assessing the subsequent effects on data 
quality. Optimized laser energy was selected for each sample type and fraction to 
avoid the presence of saturating peaks. All spectra were generated at both high and 
low laser energies with the mass focus accordingly changed to improve resolution 
within the high and low mass regions.  
8.3.9 Data analysis: 
All spectra that satisfied the same acquisition protocols and needed to be analysed 
together were placed into the same folder. Spectra were normalised by total ion 
current starting with a minimum m/z of 2500. All spectra with a normalisation factor 
outside mean + 2SD (standard deviations) were removed from the folder and regarded 
as outliers. The remaining spectra were re-normalised by total ion current.  
Expression Difference Mapping was performed by auto-detecting peaks to clusters. 
On first pass a signal / noise ratio of 5 and valley depth of 3 was used, with a 
minimum peak threshold of 20% of all spectra. On Second Pass a signal / noise ratio 
of 3 and valley depth of 1 were chosen. Cluster window was set at 1.0 peak width and 
expression difference mapping performed over m/z range of 2500 to 200,000.  
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Proprietary software was used to conduct univariate analysis of discriminatory peaks 
across groups and calculate a P value (Mann Whitney U Test) and Area under the 
ROC curve for each peak. Principal Component Plots and Heat Maps were also 
generated to spatially discriminate the data. 
8.3.10 Supervised Machine Learning – Support Vector Machine 
Data was divided into 10 equal parts used for training and testing machine learning 
classifiers. The SVM was trained with 9 parts of the data which were labelled with 
diagnostic group. The remaining unlabelled part was tested using the trained 
classifier. This cross validation process was repeated in an iterative manner using a 
different 1/10th of the data to test with. Average accuracy, sensitivity and specificity 
were calculated for the discriminatory power of the SVM. 
8.3.11 Protein concentration of PBMC lysates: 
Protein concentrations were measured using the Pierce Microplate Bicinchoninic acid 
(BCA) Protein Assay Kit, which was compatible with all components of the lysis 
buffer. Standards of Bovine serum albumin (BSA) were prepared within a working 
range of 20 – 1500µg/ml. 25µl of each standard and unknown sample were 
transferred to separate labelled wells of a 96 well plate. Working strength reagent was 
prepared by combining 50 parts of solution A (Sodium Carbonate, Sodium 
Bicarbonate, Bicinchoninic acid and sodium tartrate in 0.1 M Sodium hydroxide) with 
1 part solution B (4% cupric sulphate). 200µl of working reagent was added to each 
well and the plate incubated for 30 minutes at 370C. The absorbance was measured at 
562 nm and protein concentrations calculated from the standard curve. 
8.3.12  Optimal chip surface to identify discriminating peaks  
Before analysis of PBMC samples, experiments were designed to optimise the chip 
type and washing conditions for the SELDI-TOF proteomics tests. A total of three 
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chip surfaces, CM-10 (weak cation exchange), IMAC (metal binding surface) and 
H50 (hydrophobic) were tested.  
8.3.13 SELDI analysis of PBMC lysates on CM10 chips 
The concentration of PBMC lysate applied to chips was standardised by diluting all 
samples to a final concentration of approximately 150µg/ml with lysis buffer. 100µl 
of each sample was incubated on ice with 100µl of urea/chaps solution for 30 
minutes. CM10 chips were placed in a Bioprocessor and 75µl of Binding Buffer 
added to each well. 75µl of the sample / urea solution were then added to the bio-
processor and the protocol completed as previously described in section 8.3.5. 
8.3.14  IMAC chip surfaces. 
Chips were prepared for metal binding adding 50µl Copper(II) Sulphate solution 
followed by 150µl of double distilled water (ddH2O). Chips were equilibrated adding 
150µl Sodium Acetate buffer followed by 150µl ddH2O. Samples were diluted 1:10 
with binding buffer (0.1M NaHPO4, 0.5M Sodium chloride) and 100µl of the solution 
immediately applied to the appropriate well of the bioprocessor. Samples were 
incubated on a shaking tray for 1 hour. Chips were washed, sinapinic acid matrix 
applied and spectra read using a System 4000 Bio-rad Mass Spectrometer 
8.3.15  H-50 chip 
Chips were equilibrated with 50µl of 50% Acetonitrile followed by 150µl of binding 
buffer (10% Acetonitrile and 0.1% TFA). Samples were diluted 1:10 with binding 
buffer and 100µl of the solution immediately applied to the appropriate well of the 
bioprocessor. Samples were incubated on a shaking tray for 1 hour. Chips were 
washed, sinapinic acid matrix applied and spectra read. 
47 
 
8.3.16 Immunodepletion experiments: 
100µl of Protein G-Sepharose beads in ethanol solution were washed with Phosphate 
Buffered Saline (PBS) 3 times (centrifuge 13,000 rpm for 2 minutes between each 
wash). The pellet was re-suspended with 1ml of 5% BSA in PBS as a blocking step to 
reduce non-specific binding. The beads were left overnight with gentle rocking at 
room temperature and washed 3 times with PBS before finally being suspended in 
PBS to make a 50% slurry. 
Concurrently 10µl of non-denatured plasma was diluted with 190µl of Serum 
Amyloid A IgG Antibody (Abcam Plc ab687) and incubated overnight at room 
temperature. A control sample was also incubated with no antibody. 100µl of the 50% 
Sepharose slurry was added to the plasma-antibody sample. The combined sample 
was left to incubate for a further 3-4 hours at room temperature with continuous 
agitation. The sample was centrifuged at 13,000 rpm and supernatant taken off. The 
beads were then washed 3 times with PBS and finally with 50µl of 50% Acetonitrile 
and 0.5 % TFA. The supernatants and eluants were then denatured in Urea/chaps 
solution and applied to SELDI CM10 chips as described in section 8.3.5 above. 
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9 QUALITY CONTROL 
9.1 Introduction 
Critics of SELDI-TOF technology have raised several questions relating to variation 
in mass spectrometer stability as well as reproducibility of protein chip 
performance.[111, 117] Co-efficients of variation (CV) for absolute intensity can be 
as high as 50-60%.[118] With several potential sources of variability in the SELDI 
process, further concerns have been raised that artefacts related to sample collection 
and processing may produce observed differences as opposed to actual biological 
differences in various disease states.[113, 119] 
Many SELDI quality control studies have since been published centred primarily 
around three themes: SELDI platform reproducibility[116], variability across 
biological and technical replicates  and the detection of low quality spectra and their 
subsequent elimination.[120] Semmes et al in a large multi-centred study showed 
instrument and assay output reproducibility using the characteristics of three peaks in 
pooled quality control spectra.  Plate, chip and spot variability have been assessed 
through the use of quality control samples and replicate samples to identify systematic 
noise and bias in an experiment. 
Despite these measures experimental error is difficult to eliminate when manually 
processing hundreds of samples in replicate over several days. This has resulted in a 
drive to use automated liquid handling systems to process SELDI samples, a practice 
which has reduced the CV for peak intensity to 15-36%.[121]  
With further advances in SELDI technology the PBSIIc mass spectrometer has been 
replaced by a new generation System 4000 mass spectrometer. Changes include 
higher sensitivity, superior quantitation, higher throughput and a wider dynamic 
range.  Few studies have compared the two mass spectrometers and one study has 
suggested the benefit of increased peak detection was mostly limited to fractionated 
samples.[122] 
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In this chapter we introduce the concept of the mass spectrum, the potential sources of 
variation which can introduce analytical bias and measures that can be taken to reduce 
these. As well as exploring the different technologies available and their benefits, 
results are presented to show the stringent measures taken throughout all experiments 
to ensure only high quality data were taken forward for analysis in subsequent 
chapters. 
9.2 Methods 
9.2.1 The effect of pH and time on Mass Spectra 
Prior to sample collection in Peru a series of experiments was conducted to investigate 
optimal pH conditions and time to sample processing. Two samples of blood were 
taken from a control subject and centrifuged immediately (Time 0) and after being left 
at room temperature for 6 hours (Time 6). After centrifugation each sample was 
processed using CM10 chips and buffers from pH 4.0 to 5.0.  
9.2.2 Assessment of Mass Spectrometer Reproducibility 
Mass spectrometer reproducibility was assessed using the Bio-rad ProteinChip Check 
Kit on 3 occasions prior to each major set of experiments. Tests for detector 
sensitivity gave pass results on all occasions with signal to noise ratio (S/N) greater 
than a set level for IgG protein at concentrations of 140fmol and 10fmol. Tests for a 
peak at 5.9kDa consistently gave results <7 for mass drift and > 750 for resolution, 
giving pass results for the QC Kit. 
9.2.3 Principal Component analysis 
Principal Component Analysis is a common technique to identify patterns in data with 
many dimensions. Dimensions are compressed in such a way as to highlight their 
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principal similarities and differences. A spectrum containing hundreds of peaks can be 
summarized by a point in 3-dimensional space defined by the first 3 principal 
components. These 3 components will represent a certain percentage of the variance 
in the whole spectrum. Principal component analysis was used to investigate sources 
of variance.  
9.2.4 Assessment of Intra- and Inter-chip variability 
Quality control experiments were performed to assess intra and inter-chip variability. 
The quality control sample was manually applied to all spots on 4 CM10 chips 
generating 32 spectra using a PBSIIc mass spectrometer. The same experiment was 
later repeated using an automated liquid handling platform and a System 4000 mass 
spectrometer. Intra-chip variability was calculated for the 8 spots on each chip by 
taking the mean of the co-efficient of variation for peaks with intensity > 1µA present 
in all spectra. The mean Intra-chip variability was calculated from the 4 chips. Inter-
chip variability was calculated as the mean co-efficient of variation for peaks with an 
intensity > 1µA present in all QC spectra across all chips.  
For all subsequent case control experiments all samples were run in duplicate, quality 
control samples were placed on each chip and CV for peak intensity calculated. 
Spectra were eliminated if normalisation factors were greater than 2SD from the 
mean; PCA plots were generated for the QC samples to assess bioprocessor 
variability. 
9.3 Results 
9.3.1 The effect of pH and time on Mass Spectra 
The mass spectra generated at 3 pH values from samples centrifuged at Time 0 and 
Time 6 are shown in Figure 1. The x axis (m/z) gives a relationship of the mass of an 
ion and its charge, since most ions are singly charged this ratio given in Dalton units 
(Da) is equivalent to the mass of the peak detected. The full m/z range generated is 
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from 2500Da to 200,000Da, Figure 1 represents 6% of the total spectrum. The y axis 
reflects signal intensity a measure of the relative abundance of each ion, this is 
measured as electrical signal detected in µA.  
Each spectrum has a level of background noise, peaks are distinguished from noise by 
setting a level for the signal to noise ratio(S/N). Once this is set the number of peaks 
in each spectrum can be counted as shown in Table 1. At baseline (Time0) more 
peaks are generated in those chips processed at pH4.0. As the pH of buffers rise the 
number of peaks and their intensities decrease.  
By leaving the blood sample at room temperature for 6 hours before processing at 
each pH value the number of peaks detected increases. Both pH of buffers and the 
time from sample acquisition to centrifugation affect the nature of the mass spectrum. 
  
Number of Peaks 
 
 
 
pH 4.0 
 
pH 4.5 pH 5.0 
 
Time 0 hours 
 
 
89 
 
72 
 
73 
Time 6 hours 
 
92 99 81 
Table 1: Peaks detected at different time points and pH values 
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Figure 1: Spectra generated at 3 pH values over 2 time points 
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9.3.2 The effect of DTT degradation on spectra 
After an initial pilot study, 30 active TB patient spectra were compared with 30 
unhealthy controls. A quality control sample was placed on each chip and three 
Bioprocessors (incorporating 12 chips) run on 1 day using CM10 chips at pH 4.0. By 
plotting the first three Principal components in three dimensions for the QC samples 
we were able to assess Bioprocessor variability across the day.  
Each spot in Figure 2 represents one of the 36 QC spectra and the colour of the spot 
represents the bioprocessor in which it was applied. The closer spots are to each other 
the more similar the spectra are. As the same QC sample is applied to all chips we 
would expect the spots to be randomly distributed with no clustering of colours. Inter-
bioprocessor variability was demonstrated with clustering of the QC samples in 
Bioprocessor 3 (green). 
                       
Figure 2: PCA plot of QC samples from 3 Bioprocessors run over 1 day  
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Representative spectra from each of the 3 Bioprocessors are shown in Figure 3, here 
we see that with each successive Bioprocessor the Peaks at 33 and 66kDa representing 
albumin become bigger at the expense of other low molecular weight peaks. This 
increasing albumin binding as the day progressed was felt to be responsible for the 
Bioprocessor variability. It was hypothesised that use of a single batch of urea chaps 
solution first thawed in the morning and used throughout the day resulted in this 
variability. The green bioprocessor was processed last by which time the urea-
chaps/DTT had been at room temperature longest. 
20000 40000 60000
0
10
20
30
40
50
BIOPROCESSOR 1
0
10
20
30
40
50
BIOPROCESSOR 2
0
10
20
30
40
50
BIOPROCESSOR 3
20000 40000 60000
 
Figure 3: Representative spectra of the QC sample from each Bioprocessor  
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Urea Chaps solution contains DTT and is used to denature and solubilise proteins, the 
DTT is used as a reducing agent to break disulfide bonds; it is an unstable compound 
at room temperature. The time lapse from running the first bioprocessor to the third 
was approximately 6 hours in which time the ability of urea chaps to solubilise low 
abundance proteins may have diminished allowing albumin as a high abundance 
protein to saturate the detector in subsequent experiments, and produce bioprocessor 
associated clusters in our results. It has previously been observed that lower 
concentrations of DTT in urea chaps and solutions that have undergone 2 freeze thaw 
cycles result in increased albumin binding. 
9.3.3 Quality control and anion exchange fractionation. 
Quality control was also conducted for fractionation experiments; the QC sample was 
fractionated into 6 fractions using the anion exchange fraction method described in 
8.3.6. Each fraction was then analysed on CM10 chips as described in 8.3.5. The pre-
analytical fractionation process was included in the calculation of CV for mass 
intensity. In Figure 4 spectra of the QC sample are shown in crude and fractionated 
forms. The fractionation process separates the crude plasma proteome into a deeper 
sub-proteome; improving the resolution of some peaks (9kDa complex in fraction 2), 
allowing new peaks to be seen (13.7kDa in fraction 4) and increasing the intensity of 
other peaks (4.5kDa complex in fraction 5). 
The increased information seen with fractionation is further emphasised by the PCA 
plot seen in Figure 5. Crude plasma and each fraction are represented with a different 
coloured spot in the plot. Similar coloured spots representing the same fraction of the 
QC sample cluster well and are reproducible even after the Fractionation process is 
included in the QC analysis. Each coloured cluster of spots appears in a different 
space of the 3D- plot, confirming each fraction gives us different information about 
the deep plasma proteome. 
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Figure 4: Representative spectra from crude plasma and each fraction 
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Figure 5: PCA crude and fractionated QC sample. 
9.3.4 Automated liquid handling and use of a System 4000 mass spectrometer 
improves CV for peak data. 
Quality control experiments conducted to assess the inter and intra-chip CV for peak 
data using manual processing and a PBSIIc mass spectrometer were compared to 
those produced using an automated liquid handling system and a system 4000 mass 
spectrometer.  
The overall improvement in mean inter and intra-chip CV for peak intensity for all 
peaks in the QC sample with an intensity greater than 1 is shown in Table 2.  
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Intra-chip 
CV(%) Intensity 
 
 
Inter-chip 
CV(%) Intensity 
 
Manual + PBSIIc 
 
19.35 
 
33.04 
 
Automated + System 4000 
 
14.39 
 
19.15 
Table 2: Inter and Intra chip CV for peak Intensity.  
The greatest improvement in CV for peak intensity using an automated liquid 
handling system was seen in the inter chip variability. Automation considerably 
narrowed the gap between inter and intra-chip CV. 
9.3.5 QC in experimental data 
QC samples were applied to chips throughout each experimental comparison, 
allowing calculation of inter chip CV for peak intensity. Bioprocessor reproducibility 
was assessed for each experiment by the use of PCA plots. 
Each experimental sample was processed in duplicate and spectra normalised by total 
ion current. Where the normalisation factor (NF) was greater or less than the mean NF 
+2sd, the spectra were removed from further analysis. Where both samples were 
outside 2sd from the mean NF the whole sample was excluded from analysis. If 3 or 
more spots from the same chip were eliminated, the whole chip was repeated. 
QC data from each experiment are shown in Table 3. The mean inter-chip CV for 
peak intensity in QC samples was 19-20% in crude plasma samples, increasing to 19-
36% for fractionated samples which included the pre-analytical fractionation process 
in the QC analysis. Outlier spectra were excluded resulting in some patient samples 
being totally excluded from the analysis (if both duplicates were outliers) and other 
samples only represented by single spectra. 
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Bioprocessor variability was assessed for each experiment using PCA plots. In Figure 
6 the QC spectra are shown from 8 bioprocessors run over 2 days for the Active TB / 
Unhealthy control comparison. Unlike Figure 2 the different coloured spots are evenly 
mixed and distributed with little clustering of the spots by bioprocessor. The TB 
repeats BP (brown spots) was run on a separate day from other bioprocessors and 
shows the most degree of clustering compared to other bioprocessors. 
                
                            
Figure 6: PCA plot for 8 Bioprocessors in the active TB experiment 
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Table 3: QC data from experimental comparisons 
 
Experimental Comparison 
 
 
No. Experimental spectra 
generated 
 
 
No. QC spectra generated 
 
 
Mean NF+2SD for experimental 
data 
 
 
No. Outlier spectra excluded 
 
 
Mean Inter-chip CV(%) 
Intensity QC sample 
 
 
Crude Plasma: TB / Unhealthy 
Controls 
532 76 2.73 21 19.4 
 
Crude Plasma: Latent TB / No 
TB 
304 48 2.28 12 21 
 
Fraction1: Active TB / 
Unhealthy Controls 
432 48 1.64 12 19.7 
 
Fraction2: Active TB / 
Unhealthy Controls 
432 48 2.66 15 36.6 
 
Fraction3: Active TB / 
Unhealthy Controls 
432 48 1.96 12 27.3 
 
Fraction4: Active TB / 
Unhealthy Controls 
432 48 1.73 18 28.2 
 
Fraction5: Active TB / 
Unhealthy Controls 
432 48 2.37 16 26.4 
 
Fraction6: Active TB/ Unhealthy 
Controls 
432 48 3.18 21 33.2 
 
PBMC lysates Latent TB 
/ No TB 
 
96 14 2.49 7 25.2 
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9.4 Discussion 
Quality control experiments demonstrate that the time from sample collection to 
processing samples influences the number of peaks observed. A standard operating 
procedure of centrifuging all blood samples 6 hours after collection in Peru was 
devised to limit the introduction of this analytical time bias. 
Spectra are also sensitive to the pH of buffers and possibly to degradation of buffers 
at room temperature. The effects of storage and freeze thaw cycles were minimised by 
bulk production, aliquoting and freezing of buffer solutions which underwent one 
freeze thaw cycle prior to use. A fresh aliquot of urea/chaps solution was thawed each 
time a new bioprocessor was started. 
Instrument reproducibility was demonstrated using the Bio-rad ProteinChip Check 
Kit. Automated liquid handling steps were shown considerably to improve the CV for 
peak parameters. Other studies have widely recommended sample loading and in 
particular EAM application should be automated with the use of a constant drying 
period between applications. 
Comparison of results with other studies is complicated by the lack of a standard 
practise in the means by which CV for peak intensity is calculated. Some studies 
include all peaks in this calculation, while others assess representative peaks or those 
above a particular threshold for peak intensity. 
Very few groups have quoted CV for spectra derived from fractionation experiments 
here the additional pre-analytical fractionation process adds further experimental 
variation before the SELDI process. Koopmann et al report CV of 24-29% after a 
calculation which involved 10 randomly chosen peaks with S/N >5.[107] Rollin et al 
used an average CV for peak intensity in a method similar to the one employed here 
and achieving results for CV between 29-42%.[123, 124] The results presented here 
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for CV for peak intensity are comparable to and often better than those published 
elsewhere. 
Quality control protocols have been used to assess SELDI-TOF experiments for 
potential sources of bias and eliminate poor quality data prior to analysis. It is evident 
that standardisation of each experimental step is central to the production of 
biologically plausible and reproducible expression patterns. 
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10 PROTEOMIC PROFILES IN ACTIVE TUBERCULOSIS 
10.1 Introduction 
Each year approximately 1.7 million people die from tuberculosis, a disease which if 
diagnosed early is curable. TB needs to be distinguished from other respiratory 
diseases presenting with similar symptoms. The identification of potential biomarkers 
in blood could revolutionise TB diagnostics with cheap, accurate and rapid bedside 
diagnostic tests. Early diagnosis would prevent spread of infection and reduce death 
through early treatment. 
Diagnostic markers for tuberculosis have previously been identified using proteomic 
fingerprinting of serum. An 11.5 kDa positive biomarker identified as a truncated 
form of serum amyloid A and a 13.7 kDa negative biomarker identified as 
transthyretin were described.[85] This study used a largely African population, did 
not look at the potential confounding effects of latent TB and used a variety of 
unhealthy controls presenting with a mixture of Infectious and Inflammatory 
disorders.  
A criticism of SELDI has been the lack of multiple studies in different ethnic 
populations to support findings. The current study was designed to validate previous 
findings, in a South American population, using unhealthy controls with symptoms 
similar to TB patients (a persistent cough with one or more constitutional symptoms 
of fever, weight loss or haemoptysis). Emphasis was placed in this study in evaluating 
clinical symptoms, nutritional status and latent TB status in both TB patients and 
unhealthy controls. This clinical information was used to determine variables which 
influenced misclassification of TB patients. 
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10.2 Methods 
10.2.1 Participant recruitment 
Cases of TB were identified through positive sputum microscopy from 15 health posts 
in the region. In this way blood and sputum could be collected from TB patients 
before the initiation of treatment. Some individuals were recruited 1 to 2 days after 
starting treatment to ensure opportunities for recruitment were not being lost. 
Individuals with respiratory symptoms (termed unhealthy controls) were recruited if 
they had a productive cough and symptoms suspicious of TB. To ensure unhealthy 
controls were not cases of tuberculosis, their sputum was analysed in our laboratories 
by smear microscopy and sensitive broth culture, follow up visits were made to ensure 
respiratory symptoms had resolved and local health post books were regularly 
checked to ensure that these contacts were not subsequently diagnosed with TB. Any 
unhealthy control that subsequently tested positive for TB during the current illness 
(smear microscopy or culture positive) was re-classified in the TB group. Contacts 
less than 15 years of age were excluded because they receive prophylactic treatment 
according to local guidelines.  
10.2.2 SELDI Data analysis 
Spectra generated were analysed in different ways: graphical analytical methods such 
as heat maps, principal component analysis plots and nearest neighbour plots were 
used to identify discrimination on the basis of whole spectral data. Univariate analysis 
of discriminatory peaks was performed using a Mann Whitney-U test and Bio-rad 
proprietary software to give a P-value and area under the ROC curve for individual 
peaks. Classification accuracy, sensitivity and specificity were calculated for the 
discriminatory performance of Support Vector Machines. 
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10.3 Results 
10.3.1 Demographics 
A total of 157 TB patients were recruited into the study, 107 of these patients received 
no treatment for TB prior to recruitment whilst 50 had 1-2 days of treatment. 112 
unhealthy controls were recruited. The initial crude plasma proteomic profile study 
was conducted using all 157 TB patients and 112 unhealthy controls. Subsequently 
the experiments on fractionated plasma were performed using 112 unhealthy controls 
and only the 107 patients who received no TB treatment. 
Demographic data for the participants in this study is shown in Table 4. On average 
TB patients had a lower BMI (mean 21.6) than unhealthy controls (mean 24.1). As 
would be clinically expected TB patients presented with more chronic symptoms of 
greater duration than unhealthy controls. Despite this controls still had a productive 
cough for a median of 15days. There was no statistically significant difference 
between the times from sample collection to centrifugation between the 2 groups. 
54% of unhealthy controls also had latent TB as determined by the QFN assay. 
10.3.2 PCA: TB against unhealthy controls crude plasma proteome 
The ability of the whole proteomic profile to discriminate between TB patients and 
unhealthy controls is shown in Figure 7 as a principal component analysis plot. The 
points represent whole SELDI spectra of the samples. Spectra of TB samples were 
colour coded blue and unhealthy controls red. The plot shows the majority of TB 
patients cluster together in the background with the red unhealthy control dots being 
in the forefront at the bottom of the plot. There is however a more clear distinction 
seen in the clustering with the majority of spots both red and blue found on the left of 
the plot and a smaller cluster found to the right of the plot.  
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In Figure 8 we see a variation of the principal component plot, a nearest neighbour 
social network plot. Here each spot once again represents a spectrum, red for 
unhealthy controls and blue for TB patients. The spots are joined to their 5 nearest 
neighbours depending on spectral similarities. The colour of the connections reflects 
the concurrence of connections, blue lines join TB spectra to other TB spectra, red 
lines join controls to controls and green lines represent mismatched connections. 
We now see that TB patients are a much more heterogeneous group than seen on the 
previous plot. In particular 3 clearly defined groups form amongst the TB patient 
spectra with 2 being more closely related than the third. The unhealthy controls form 
2 groups which still share some similarities with TB patients. Very few green 
connections are seen, although mismatches still clearly occur. Some TB patients have 
more connections than others, suggesting the concept of the “representative” TB 
patient spectrum 
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Table 4: Demographic, nutritional and clinical details of TB patients and unhealthy controls 
 
 
 
Active TB No Tx 
 
Active TB 1-2d Tx 
 
Active TB total 
 
Unhealthy Controls 
 
Numbers 107 50 157 112 
Median Age (IQR) 29 (23-37) 27.5 (20-46) 29 (22-38) 32 (25-47) 
Female (number(%)) 44 (41%) 26 (52%) 70(45%) 72 (66%) 
Mean BMI (SD) 21.7 (3.1) 21.4 (2.9) 21.6 (3.0) 24.1 (4.7) 
Mean days fever(SD) 9 (17) 13 (29) 10.5 (22) 2.1 (5.2) 
Median days fever (IQR) 2 (0-12) 3 (0-7.5) 2 (0-10) 0 (0-2) 
Median days sputum (IQR) 30 (7-45) 21 (7-45) 26 (7-45) 15 (7-28) 
Median weeks weightloss (IQR) 4 (2-12) 4 (1.5-8) 4 (2-10) 2 (0-4) 
Median days Night sweats (IQR) 6 (0-15) 7 (0.5-30) 7 (0-15) 0 (0-3) 
Median days Tiredness (IQR) 21 (7-31) 30 (14-60) 24 (7-45) 7 (0-30) 
TB tube [IFN] (IQR) 1.6 (0.6-4.8) 1.8 (0.9-3.9) 1.7 (0.6-4.5) 0.31 (0.03-2.7) 
Time to centrifugation (STATA units) 0.257 (0.25-0.271) 0.260 (0.253-0.281) 0.257 (0.25-0.271) 0.252 (0.25-0.257) 
No QFN +ve (%) 84 (90%) 42 (87.5%) 126 (89%) 51 (53.7%) 
Past  TB 26 (26%) 8 (17%) 34 (23%) 20(19%) 
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Both plots show how TB patients can be discriminated to an extent from unhealthy 
controls but not entirely separated on the basis of crude plasma spectrums alone. 
 
 
 
Figure 7: Crude plasma Principal Component Analysis plot TB and unhealthy controls.  
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Figure 8: Nearest neighbour social network plot TB and unhealthy controls                     
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10.3.3 Heat map: TB patients unhealthy controls 
Global protein expression profiling is best seen in a heat map. Here each vertical line 
represents a TB patient or unhealthy control and each horizontal line a protein with a 
particular molecular mass. Areas where a protein is present in high abundance are 
seen in red and low abundance in green. The heat map in Figure 9 shows the labelled 
spectra patterns from active TB patients and unhealthy controls. The most striking 
area of up-regulation (red) in TB patients is seen in the 11kDa region where a series 
of protein peaks are seen in red amongst TB patients. A parallel area of upregulation 
is seen at 5.5kDa and a third smaller area seen at the 21kDa region. These areas 
represent potential biomarkers for active tuberculosis 
10.3.4 Univariate analysis: active TB and unhealthy controls in crude plasma. 
Mann Whitney U tests were carried out to determine which peaks were significantly 
different between active TB and unhealthy controls. In Table 5 only those 
discriminatory peaks with an area under the ROC curve greater than 0.8 and a mean 
intensity greater than 1 are shown. 8 of these peaks come from the 11.5kDa region, 
another 5 come from a 5.8kDa region and 2 appear in the 21kDa region as reflected in 
the heat map. 
Inspecting the spectra in the 5.8 and 11.5kDa regions (Figure 10) reveals a complex of 
peaks at both these regions which is more abundant in patients with active TB. Using 
the capacity of the Bio-rad software to detect double charged ions it is probable that 
both complexes represent different ionisation states of the same group of proteins i.e. 
the 5.8kDa complex represents the double charged ions of the protein in the 11.5kDa 
complex.  
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Figure 9: Heat map active TB and unhealthy controls using whole spectral data from crude plasma 
11.5kDa 
21kDa 
5.5kDa 
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m/z 
 
P-value 
 
ROC 
 
Mean Intensity 
 
 
11479.10 6.26E-43 0.859 9.257 
 
11628.15 1.95E-42 0.853 9.265 
 
10834.38 4.58E-43 0.851 1.493 
 
5811.16 5.85E-42 0.846 5.211 
 
5732.36 2.84E-40 0.846 3.974 
 
11433.71 2.50E-40 0.843 8.282 
 
11385.55 3.32E-41 0.838 4.690 
 
11543.80 1.58E-39 0.836 14.182 
 
20884.58 3.63E-37 0.833 3.115 
 
11691.84 4.97E-39 0.830 26.495 
 
5759.58 2.56E-38 0.828 7.399 
 
5837.56 1.69E-35 0.813 14.401 
 
5941.09 1.20E-35 0.811 3.436 
 
11898.67 2.80E-33 0.803 4.209 
 
20593.22 4.00E-32 0.803 2.270 
 
Table 5: Discriminatory peaks TB from unhealthy controls using crude plasma protein spectra 
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Figure 10: Mass spectra comparing 11.5kDa and 5.8kDa peaks in TB and unhealthy controls 
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The complex at 11.5kDa is not exclusive to TB patients and does appear in unhealthy 
controls. In Figure 11, we see that the morphology of the complex is distinctly 
different between TB patients and controls. The complex has many more peaks and 
shoulders in TB patients than in unhealthy controls, with the suggestion of greater 
post-translational modification of this protein in TB than other respiratory diseases. 
The protein at 21kDa, which again is raised in TB patients compared to unhealthy 
controls, is shown in Figure 12. 
                      
Figure 11: Mass spectra comparing 11.5kDa peak complex in TB and unhealthy controls 
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Figure 12: Mass spectra comparing 21kDa peak complex in TB and unhealthy controls 
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10.3.5 Serum Amyloid A is elevated in TB patients compared to unhealthy 
controls 
Agranoff et al had previously characterised the 11.5kDa protein as Serum Amyloid A 
(SAA)[85]. The Immunodepletion experiment conducted to confirm the identity of the 
11.5kDa protein is shown in Figure 13. In crude plasma (a) we see the presence of the 
protein complex at 11.5kDa. When SAA antibodies are added, there is depletion of 
this complex (b); once the beads containing antigen antibody complex are washed the 
Serum Amyloid A protein re-appears in the eluate (c). 
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Figure 13: Immunodepletion of 11.5kDa peak with SAA specific antibody 
(a) 
(c) 
(b) 
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10.3.6 Support Vector Machine: active TB and unhealthy controls, crude plasma  
A SVM was able to discriminate and classify TB patients from unhealthy controls 
using the whole pattern from crude plasma with an accuracy of 84%. The sensitivity, 
Specificity, positive predictive value (PPV) and negative predictive value (NPV) of 
this classifier along with standard deviations is shown in Table 6 with the ROC curve 
shown in Figure 14. On the basis of the whole crude plasma spectrum the classifier 
does well to pick out TB cases from controls, but the specificity to rule out TB in 
unhealthy controls and the negative predictive value is not as good.  
 
Sensitivity (STD) 
 
Specificity 
(STD) 
 
Accuracy (STD) 
 
PPV 
(STD) 
 
NPV 
STD) 
 
 
0.87(0.035) 
 
 
0.79(0.056) 
 
 
0.84(0.028) 
 
 
0.86(0.031) 
 
 
0.81(0.043) 
 
Table 6: SVM discriminating TB from unhealthy controls using crude plasma 
                             
Figure 14: ROC curve of active TB SVM. 
 
Sensitivity 
1-Specificity 
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10.3.7 Factors predicting misclassification of TB patients by SVM classifier 
based on whole crude plasma spectrum 
In order to explore the clinical, nutritional or diagnostic parameters which predict 
misclassification of TB patients by the SVM a logistic regression analysis was 
performed. The results of this analysis are shown in Table 7. All variables with a p 
value of less than or approaching 0.05 were included in a multivariate analysis. The 
most striking finding was that the body mass index (BMI) was predictive of 
misclassification of TB patients i.e. those TB patients with a high BMI are more likely 
to be misclassified.  The whole crude plasma proteome may represent a surrogate for 
BMI or nutritional state and therefore not be a specific diagnostic tool. 
Other clinical factors relating to duration of cough and grade of smear positivity had 
odds ratios less than 1, reflecting a protective effect against misclassification. 
Duration of weight loss and night sweats were also approaching statistical 
significance in a univariate analysis, reflecting a propensity for clinically advanced 
TB to be correctly classified by the SVM. 
10.3.8 Principal Component Analysis TB against Unhealthy controls 
fractionated plasma proteome 
In order to overcome the nutritional confounding effect seen with crude plasma, 
experiments were repeated with anion exchange fractionation of each plasma sample. 
In view of the logistics and cost of randomising active TB and unhealthy controls on 
fractionation plates these experiments were conducted on 112 unhealthy controls and 
the 107 TB patients who received no treatment prior to recruitment. 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 1.01(0.97-1.05) 0.626   
Sex (F) 2.7 (0.87-8.3) 0.083   
BMI 1.38 (1.13-1.69) 0.002 1.8 (1.28-2.58) 0.001 
Collection Date 1.00 (0.99-1.00) 0.848   
Sputum smear 0* 0    
Sputum smear 1+ 0.63 (0.1-3.9) 0.624   
Sputum smear 2+ 0.61 (0.1-2.7) 0.522   
Sputum smear 3+ 0.17 (0.02-1.00) 0.05 0.2 (0.02-2.01) 0.008 
Days cough dry 0.95 (0.92-0.99) 0.014 0.95 (0.9-0.99) 0.013 
Days fever 0.89 (0.79-1.02) 0.109   
Weeks weight loss 0.88 (0.77-1.02) 0.063   
Days night sweats 0.93 (0.86-1.01) 0.072   
Table 7:  Univariate and Multivariate logistic regression analysis of factors which predict misclassification of TB patients by a SVM using proteomic profile from 
Crude Plasma 
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Each plasma sample was fractionated into 6 fractions according to the isoelectric 
point of the proteins within it, ranging from pH 9 to 3 and an organic protein fraction. 
The PCA plot for each fraction is shown in Figure 15. Each spot on the plot is a 
spatial representation of a spectrum, the closer the individual coloured spots are to 
each other (red TB, blue unhealthy control) the more similar the spectra are. Fractions 
1,4,5 and 6 i.e. pH 9,4,3 and organic respectively achieve good clustering of red and 
blue spots suggesting good discrimination in these fractions. The distribution in 3D 
space by which this discrimination is achieved is different within all of the fractions, 
reflecting different elements of the spectrum (proteins) being used to differentiate the 
two groups. 
10.3.9 Performance of Support Vector Machines in discriminating between 
Active TB and unhealthy controls using fractionated plasma profiles 
Support Vector Machines were developed using the spectral peaks from each fraction. 
Each fraction gave different information about the deep plasma proteome and so 
classifiers achieved different sensitivities and specificities when discriminating 
between active TB and unhealthy controls (Table 8). Fractions 1,4,5 and 6 performed 
the best as predicted from the PCA plots. The specificity of the classifiers has also 
improved when using fractionated plasma instead of crude plasma. 
When the logistic regression analyses were repeated for each fraction (Tables 9-14), 
BMI was only predictive of misclassification in TB patients in one fraction Fraction 3 
(OR 1.25 (1.02-1.54), p 0.033). This fraction produced one of the weakest classifiers. 
Once again factors suggesting chronicity of TB symptoms were protective against 
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                           Figure 15: Fractionated plasma PCA plot TB and unhealthy controls. 
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Table 8: Performance of SVMs in discriminating TB from unhealthy controls using fractionated plasma
 
Fraction 
 
Sensitivity (STD) 
 
Specificity (STD) 
 
Accuracy (STD) 
 
PPV(STD) 
 
NPVSTD) 
 
1 0.90(0.095) 0.88(0.067) 0.89(0.04) 0.88(0.058) 0.91(0.066) 
 
2 0.78(0.057) 0.82(0.051) 0.80(0.035) 0.81(0.043) 0.80(0.042) 
 
3 0.81(0.063) 0.89(0.043) 0.85(0.035) 0.88(0.043) 0.84(0.045) 
 
4 0.86(0.051) 0.86(0.045) 0.86(0.032) 0.86(0.04) 0.87(0.042) 
 
5 0.87(0.046) 0.89(0.046) 0.88(0.029) 0.89(0.041) 0.87(0.038) 
 
6 0.85(0.051) 0.92(0.042) 0.88(0.031) 0.91(0.041) 0.86(0.039) 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 1.00(0.94-1.07) 0.893   
Sex (F) 1.43 (0.78-7.48) 0.665   
BMI 0.96 (0.72-1.25) 0.745   
Collection Date 1.00 (1.00-1.01) 0.123   
Sputum smear 0* 0    
Sputum smear 1+ - -   
Sputum smear 2+ 1.11 (0.79-15.5) 0.938   
Sputum smear 3+ 0.17 (0.01-3.23) 0.240   
Days cough 0.95 (0.9-1.01) 0.121   
Days fever 0.92 (0.79-1.09) 0.353   
Weeks weight loss 0.89 (0.75-1.08) 0.265   
Days night sweats 0.99 (0.95-1.04) 0.827   
Table 9: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 1 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 0.99 (0.95-1.03) 0.695   
Sex (F) 3.15 (1.19-8.4) 0.021 2.92 (0.64-13.4) 0.168 
BMI 1.19 (1.01-1.41) 0.041 1.21 (0.94-1.57) 0.131 
Collection Date 1.00 (1.01-1.00) 0.144   
Sputum smear 0* 0    
Sputum smear 1+ 0.38 (0.05-3.00) 0.355   
Sputum smear 2+ 0.30 (0.04-1.86) 0.198   
Sputum smear 3+ 0.09 (0.01-0.62) 0.014 0.06 (0.01-0.56) 0.014 
Days cough dry 0.98 (0.96-1.00) 0.041 0.98 (0.96-1.00) 0.128 
Days fever 0.98 (0.94-1.02) 0.286   
Weeks weight loss 0.94 (0.87-1.03) 0.188   
Days night sweats 0.98 (0.94-1.01) 0.182   
Table 10: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 2 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 1.00(0.95-1.05) 0.930   
Sex (F) 1.83 (0.52-6.4) 0.940   
BMI 1.25 (1.02-1.54) 0.033 1.25 (1.02-1.54) 0.033 
Collection Date 1.00  (0.99-1.00) 0.521   
Sputum smear 0* 0    
Sputum smear 1+ 0.18 (0.13-2.6) 0.209   
Sputum smear 2+ 0.22 (0.08-1.77) 0.155   
Sputum smear 3+ 0.23 (0.03-1.65) 0.146   
Days cough 0.99 (0.98-1.01) 0.480   
Days fever 0.90 (0.78-1.04) 0.160   
Weeks weight loss 0.93 (0.82-1.04) 0.210   
Days night sweats 0.98 (0.94-1.02) 0.397   
Table 11: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 3 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 0.98 (0.93-1.03) 0.463   
Sex (F) 1.22 (0.41-3.7) 0.712   
BMI 1.16 (0.97-1.39) 0.095 1.17 (0.78-1.77) 0.423 
Collection Date 1.00 (1.00-1.00) 0.967   
Sputum smear 0* 0    
Sputum smear 1+ 1.14  (0.14-9.29) 0.901   
Sputum smear 2+ 0.32 (0.04-2.36) 0.264   
Sputum smear 3+ 0.09 (0.01-0.82) 0.034 0.03 (0.001-1.34) 0.071 
Days cough dry 0.95 (0.91-0.99) 0.012 0.9 (0.82-0.99) 0.032 
Days fever 0.81 (0.66-1.00) 0.057 0.19 (0.02-1.89) 0.157 
Weeks weight loss 1.01 (0.99-1.03) 0.204   
Days night sweats 0.94 (0.88-1.01) 0.100   
Table 12: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 4 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 0.99(0.94-1.04) 0.666   
Sex (F) 1.26 (0.39-4.05) 0.694   
BMI 1.14 (0.94-1.40) 0.191   
Collection Date 1.00 (1.00-1.00) 0.031 1.00 (1.00-1.00) 0.094 
Sputum smear 0* 0    
Sputum smear 1+ 2.5 (0.21-29.2) 0.465   
Sputum smear 2+ 0.77 (0.07-8.4) 0.830   
Sputum smear 3+ 0.22 (0.17-2.91) 0252   
Days cough dry 0.97 (0.93-1.00) 0.063 0.98 (0.94-1.02) 0.362 
Days fever 0.84 (0.68-1.03) 0.094 0.84 (0.69-1.02) 0.095 
Weeks weight loss 0.78 (0.62-0.99) 0.025 0.80 (0.64-0.99) 0.036 
Days night sweats 0.94 (0.87-1.02) 0.126   
Table 13: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 5 
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Univariate Analysis Multivariate analysis  
Variable 
Odds Ratio P value Odds Ratio P value 
Age 1.01(0.97-1.06) 0.547   
Sex (F) 1.8 (0.6-5.4) 0.297   
BMI 1.21 (1.01-1.46) 0.038 1.14 (0.95-1.39) 0.162 
Collection Date 1.00 (1.00-1.01) 0.447   
Sputum smear 0* 0    
Sputum smear 1+ 1.67 (0.13-20.58) 0.690   
Sputum smear 2+ 0.58  (0.05-6.73) 0.661   
Sputum smear 3+ 0.61 (0.06-6.32) 0.679   
Days cough  0.99 (0.96-1.01) 0.180   
Days fever 0.81 (0.66-1.00) 0.055 0.83 (0.67-1.02) 0.077 
Weeks weight loss 0.94 (0.85-1.03) 0.199   
Days night sweats 0.93 (0.86-1.01) 0.071 0.96 (0.68-1.04) 0.103 
Table 14: Univariate and Multivariate logistic regression analyses of factors which predict misclassification of TB patients by a SVM, using the proteomic profile 
from fraction 6 
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misclassification of TB in many of the fractions: sputum smear 3+ in Fraction 2 [OR 
0.09 (0.01-0.62), p 0.014], number of days of cough Fraction 4 [OR 0.9 (0.82-0.99), p 
0.032] and number of weeks of weight loss [OR 0.80 (0.64-0.99), p 0.036].  
10.3.10Univariate analysis: discriminatory peaks between active TB and 
unhealthy controls in fractionated plasma 
As with crude plasma spectra, Mann Whitney U tests were conducted on the data 
from all fractionated plasma proteomes to determine statistically significant peaks 
which discriminate between TB and unhealthy controls. Potential positive biomarkers 
with an area under the ROC curve greater than 0.8 and negative biomarkers with an 
area under the ROC curve less than 0.2 are shown in Table 15 and Table 16 
respectively. The fraction and laser intensity (low/high) at which these peaks are most 
prominent are also shown in the tables.  
The complex at 11.5kDa and its double charged complex at 5.8kDa once again make 
up the bulk of these discriminatory peaks and appear in many of the fractions. A new 
complex of proteins at 4.1 to 4.6 kDa, which were not detected in crude plasma also 
appear as highly discriminatory in distinguishing TB from Unhealthy controls. The 
mean intensity of the protein at 4.4 kDa is almost 300µA in fraction 5 making it a 
more favourable potential biomarker (Figure 16). Once again these markers appear in 
complexes and may represent disease specific post translational modification of 
proteins. 
The fractionation experiments also reveal many potential negative biomarkers which 
were not detected in crude plasma. Many of these markers are detected at a high 
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molecular weight using high laser energy, and may not therefore have been detected 
in crude plasma amongst the multitude of other proteins.  
m/z mean 
 
P value 
 
ROC 
 
Intensity 
 
Laser 
 
 
Fraction 
 
3247.93 5.55E-34 0.84 41.86 low 1 
4136.75 2.34E-29 0.81 24.74 low 5 
4479.04 7.28E-31 0.82 298.16 low 5 
4685.76 1.79E-29 0.82 24.59 low 5 
5514.05 3.81E-30 0.81 4.44 low 1 
5716.58 9.25E-30 0.81 9.13 low 1 
5719.17 1.59E-33 0.83 9.58 high 1 
5758.11 4.02E-33 0.82 8.35 low 1 
5771.71 2.94E-33 0.83 13.33 low 6 
5813.70 2.24E-33 0.84 8.84 high 1 
5826.12 4.39E-40 0.87 10.49 low 1 
5862.65 2.28E-35 0.85 20.76 low 6 
5917.78 3.30E-29 0.80 7.97 low 1 
10834.18 2.62E-42 0.87 4.67 high 1 
10866.03 1.13E-40 0.87 4.53 low 1 
11103.24 1.15E-28 0.80 1.81 low 1 
11417.03 7.80E-38 0.85 19.60 low 1 
11449.22 2.21E-39 0.85 38.32 high 1 
11499.07 8.18E-40 0.85 29.53 low 1 
11553.49 2.56E-37 0.86 6.17 low 5 
11564.13 7.01E-37 0.85 5.55 low 4 
11566.06 3.29E-39 0.86 48.96 low 6 
11687.35 6.39E-39 0.86 47.51 high 1 
11703.24 3.04E-39 0.86 38.21 low 1 
11722.81 1.01E-35 0.85 75.17 low 6 
11740.63 5.33E-34 0.84 8.77 low 4 
11744.56 1.56E-35 0.85 9.82 low 5 
11888.47 6.01E-36 0.83 7.66 low 1 
11918.44 4.03E-35 0.85 13.61 low 6 
12728.36 2.04E-30 0.82 1.38 low 1 
14626.55 5.87E-40 0.86 4.50 high 1 
14731.31 1.50E-35 0.85 3.76 low 1 
23065.13 4.59E-29 0.81 2.03 high 4 
      
Table 15: Potential positive biomarkers to discriminate TB from unhealthy controls using the 
fractionated plasma proteome 
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M/z mean 
 
P value 
 
ROC 
 
intensity 
 
Laser 
 
 
Fraction 
 
2647.04 2.72E-28 0.20 11.50 low 5 
2944.61 1.17E-36 0.16 16.95 low 1 
6898.07 5.21E-27 0.20 12.57 low 1 
13802.83 2.24E-27 0.20 38.59 low 5 
13931.74 4.05E-32 0.17 8.65 low 1 
14068.78 2.01E-27 0.20 2.69 high 5 
14109.53 6.90E-29 0.20 2.25 low 1 
21077.16 7.54E-30 0.19 0.80 high 4 
21134.92 1.70E-31 0.19 0.66 low 1 
28072.14 9.12E-32 0.18 5.45 high 1 
28200.11 5.21E-31 0.18 2.78 low 4 
28274.76 4.72E-32 0.18 2.15 high 6 
33433.48 1.29E-27 0.20 9.94 low 1 
66631.55 1.86E-28 0.20 89.05 high 1 
66969.15 9.41E-31 0.19 51.19 low 1 
73634.02 4.95E-28 0.20 2.28 low 5 
133961.46 4.41E-28 0.20 10.81 high 6 
134572.11 5.55E-29 0.20 8.33 low 1 
      
Table 16: Potential negative biomarkers to discriminate TB from unhealthy controls using the 
fractionated plasma proteome 
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Figure 16: Mass spectra comparing 4.4kDa peak complex in TB patients and unhealthy controls 
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10.4 Discussion 
At the initial pattern recognition stages we note from the principal component plots 
that TB can not completely be discriminated from unhealthy controls on the basis of 
the whole pattern alone. The nearest neighbour social network plot showed that TB is 
a heterogeneous disease. As a clinical entity we know that patients with TB present at 
different stages and with different symptoms. Active TB can range from being a sub-
clinical illness which is contained by the host in one patient to manifesting as a 
chronic febrile illness with weight loss and night sweats in another. We immediately 
see on a whole pattern level that a single proteomic profile is unlikely to diagnose all 
TB patients. 
Nevertheless SVM performed well in using the whole pattern to discriminate active 
TB from individuals presenting with similar symptoms. The sensitivity, specificity 
and accuracy of this discrimination were dependent upon whether crude plasma 
patterns were used alone or whether a deeper fractionated proteome is used. 
Crude plasma proteomic profiles were confounded by the effects of BMI, and 
potentially have the limitation of reflecting an individual’s nutritional state more so 
than any specific disease state. Pre-analytical processing of plasma samples with 
anion-exchange fractionation produced more sensitive and specific classifiers, 
revealed previously unseen potential biomarkers and was not confounded by the 
effects of BMI.  
Serum Amyloid A was validated with a second SELDI-TOF study as a strong 
potential Biomarker for TB. Furthermore the pattern of peaks within the SAA 
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complex could well differentiate TB from other respiratory diseases were this acute 
phase protein is raised. 
Machine Learning classifiers are highly dependent on the correct classification of 
cases and controls. In Active TB sputum smear and culture positivity provides gold 
standard investigations by which to train a classifier. When investigating proteomic 
profiles for Latent TB we are immediately faced with the lack of a gold standard 
diagnostic test and hence an inherent difficulty in training classifiers. In the next 
chapter we explore the prospect of defining Latent TB. 
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11 DEFINING LATENT TB 
11.1 Introduction 
Screening for latent TB has important implications for identifying infected 
individuals, providing prophylactic treatment[125] and reducing disease transmission. 
Diagnostic tests for latent TB are also vital in contact tracing[126], epidemiological 
studies [127] and monitoring of Health Care workers.[128] 
Latency is a clinical state of quiescence reflecting presence of tuberculous bacilli in 
the host but a lack of disease activity. There is no gold standard test that identifies the 
presence of bacilli in individuals with latent TB. Diagnostic tests for latent TB such as 
the TST and IFN-γ assays are dependent on measuring the host response to the 
pathogen.  
The aim of this chapter is to compare the TST and the QFN assay to establish which 
of the two tests would most accurately define latent TB in our population.  
Studies which evaluate tests for latent TB overcome the drawback of no gold standard 
by using surrogates for latent TB such as active TB or past medical history of TB. [71, 
129, 130] It is also possible to compare the 2 tests, calculate a level of agreement 
between them and further investigate the factors associated with discordant 
result,[131-134] some studies have divided the population into groups reflecting the 
risk of exposure to TB and demonstrated a dose-response effect with new tests 
identifying more latent TB infection in the group most heavily exposed.[135, 136]  
Both the IFN-γ assay and TST have arbitrarily chosen cut-off values and some 
discordance will occur close to these cut off values.[137, 138] Cut off values can only 
be meaningfully discussed in a specific context, and may vary with population 
depending on TB disease burden and vaccination rates.[74, 139] This statistical 
analysis was conducted specifically to evaluate the performance of these 2 tests in our 
shanty town population so that machine learning classifiers could be trained with 
accurately defined cases and controls. 
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11.2 Methods 
The population was divided into 6 epidemiological risk groups: no known contact 
with TB patients, past contact with TB patients, present house contact with a TB 
patient, present room contact, past medical history of TB and current active TB.  
ROC curves were produced using epidemiological risk to predict the likely presence 
or absence of latent TB. No known contact with a TB patient was used as a surrogate 
for absence of latent TB and past medical history of TB and active TB used as 
surrogates for the presence of latent TB. Appropriate cut of values for our population 
were determined for the TST (mm) and QFN (corrected concentration of IFN-γ in the 
TB antigen tube). 
The prevalence of latent TB was determined for each test in each epidemiological risk 
group. Indeterminate test results for the QFN assay were not included in the analysis 
and patients with active TB did not receive a TST. The relationship of household 
contacts to TB patients was used as a further marker of gradient of exposure to TB. 
For individuals who had both tests performed, 2 by 2 contingency tables were 
produced and the percentage agreement and Cohen’s kappa statistic used to evaluate 
concordance. Univariate logistic regression analysis was performed to assess factors 
associated with TST positivity and QFN positivity as well as factors associated with 
discordance. Variables that were or approached statistical significance on univariate 
analysis were included in multivariate analysis.  
On the basis of this analysis the test which gave the most accurate definition of latent 
TB in our population was used for the classification of subsequent proteomic profiles. 
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11.3 Results 
11.3.1 Number of participants and demographics 
In total data from 1,907 TST and 1,352 QFN assays was analysed, 992 participants 
had data available for both tests.  
Participants were divided into 5 or 6 groups on the basis of epidemiological risk of 
latent TB (Figure 17). Where an individual had more than one risk for latent TB the 
greatest of these risks was taken to classify.  
Table 17 summarises baseline characteristics of individuals who had a TST and those 
who had the QFN-gold assay performed, there is no significant difference between the 
2 groups studied. The baseline characteristics of each epidemiological risk group 
studied are shown in Table 18 and Table 19. Over 80% of individuals in our 
population received a BCG vaccination, with over 50% having multiple BCG scars. 
11.3.2 Cut Of values for TST and IFN-g assay 
A ROC curve (Figure 18) was plotted using the corrected IFN-γ concentration from 
the TB antigen tube from 290 individuals with no known contact with TB patients and 
308 individuals with a past medical history of TB or active TB. The manufacturers cut 
off value of 0.35 IU correctly classified 73.6% of individuals, providing a sensitivity 
of 80.2%, specificity of 65.9% and area under the ROC curve of 0.756. Figure 19 
shows a similar ROC analysis performed for the TST using data from 250 individuals 
with no known contact with TB patients and 190 individuals with a past medical 
history of TB. The internationally recognised cut off value of 10mm for a positive test 
gave a sensitivity of 75.65% and specificity of 64% in this population. 
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Figure 17: Flowchart of epidemiological risk for latent TB  
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Tuberculin Skin Test 
n=1,907 
 
 
Quantiferon-Gold 
n=1,352 
 
Demographics 
 
Age mean(SD)  
 
 
 
 
33.4 (14.2) 
 
 
 
33.9 (14.4) 
Female number (%) 
 
1,211 (63.5%) 817 (60.7%) 
Past TB number (%) 
 
190 (10%) 157 (12%) 
BCG scars number (%) 
   0 scars 
   1 scar 
 >2 scars 
 
 
222 (11.7%) 
668 (35.1%) 
1,011 (53.2%) 
 
167 (12.4%) 
498 (37.2%) 
675 (50.4%) 
Reported TB contact  
 
Nutritional factors 
 
767 (40.6%) 541 (42%) 
BMI mean (SD) 
 
25.22 (4.4) 25.09 (4.6) 
CAMA mean (SD) 
 
40.05 (11.2) 40.07 (11.2) 
Socio-economic factors 
 
  
Brick/Stone walls numb (%) 
 
916 (53%) 626 (53%) 
Dirt Floor number (%) 
 
554 (32%) 390 (32%) 
Headcount mean (SD) 
 
5.1 (2.3) 5.1 (2.4) 
Private toilet number (%) 
 
653 (49.1%) 908 (48.8%) 
 
Table 17: Characteristics of TST / QFN study population 
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Table 18: Characteristics of participants who received a TST by epidemiological risk group 
Table 19: Characteristics of participants who received a QFN-gold assay by epidemiological risk group 
  
No Known Contact 
(n=250) 
 
 
Past Contact 
(n=164) 
 
Present Home Contact 
(n=797) 
 
Present Room Contact 
(n=503) 
 
PMH TB 
(n=190) 
 
Age median (IQR) 
 
 
27 (19-41) 
 
36.5 (26-48.5) 
 
28 (20-40) 
 
31 (23-45) 
 
36 (28-47) 
Female number (%) 
 
155 (62.3%) 121 (73.8%) 494 (62%) 330 (65.5%) 110 (57.9%) 
BCG Vaccination      
  0 BCG scars 25 (10%) 22 (13.4%) 80 (11.1%) 58 (11.6%) 28 (14.7%) 
 1 BCG scar 110 (44.2%) 58 (35.4%) 274 (34.5%) 160 (31.9%) 66 (34.7%) 
>2 BCG scars 114 (45.8%) 84 (51.2%) 431 (54.4%) 284 (56.6%) 96 (50.6%) 
 
BMI mean (SD) 
 
25.2 (4.6) 
 
26.3 (4.5) 
 
26.6 (4.1) 
 
25.9 (4.6) 
 
25.1 (4.3) 
  
No Known Contact 
(n=290) 
 
Past Contact 
(n=178) 
 
 
Present Home Contact 
(n=346) 
 
Present Room Contact 
(n=230) 
 
Active TB 
(n=144) 
 
PMH TB 
(n=164) 
 
Age median (IQR) 
 
 
28 (19-41) 
 
33 (25-46) 
 
28 (22-42) 
 
32.5 (24-46) 
 
28 (22-38) 
 
35 (28-45.5) 
Female number(%) 
 
171 (59.2%) 128 (71.9%) 217 (62.7%) 156 (67.8%) 65 (46.8%) 80 (48.8%) 
BCG Vaccination       
      0 BCG scars 31 (10.8%) 23 (12.9%) 44 (12.8%) 21 (9.1%) 19 (13.8%) 29 (18%) 
      1 BCG scar 113 (39.2%) 65 (36.5%) 121 (35.1%) 84 (36.5%) 60 (43.5%) 55 (34.2%) 
    >2 BCG scars 144 (50%) 90 (50.6%) 180 (52.1%) 125 (54.4%) 59 (42.7%) 77 (47.8%) 
 
BMI mean (SD) 
 
25.3 (4.6) 
 
26.8 (4.8) 
 
25.1 (4.2) 
 
26.1 (4.8) 
 
21.9 (3.6) 
 
24 (4.1) 
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Figure 18: ROC curve for QFN assay  
           
Figure 19: ROC curve for TST 
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11.3.3 Prevalence of Latent in different epidemiological risk groups 
The prevalence of latent TB in each epidemiological risk group was calculated 
quantitatively using the above cut off values for positive QFN assay (Figure 20) and 
TST (Figure 21). Digits within the bars represent the numbers from which percentages 
were calculated and error bars on the figures indicate 95% CI. As the gradient of 
exposure increases the number of individuals with a positive test result 
proportionately rises. When past history of TB is used as a surrogate for latent TB the 
sensitivity of the TST is 76% and the QFN-gold assay is 80%. If the lowest exposure 
group is used as a surrogate for no latent TB then both tests have a specificity of 
approximately 65%. Neither test discriminates individuals with a past history of TB or 
active TB from individuals with close contact to TB patients.  
Figure 22 and Figure 23 show how the QFN and TST vary in household contacts with 
the relationship to the TB patient. Both tests show greater rates of latent TB amongst 
partners of TB patients who would presumably have had greater levels of exposure to 
the patient. 
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Figure 20: Prevalence of latent TB by QFN assay in 6 different epidemiological risk groups 
 
 
 
 
 
 
 
Figure 21: Prevalence of latent TB by TST in 5 different epidemiological risk groups 
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Figure 22: QFN result of household contacts by relation to TB patient 
 
 
 
 
 
 
 
 
Figure 23: TST of household contact by relation to TB patient 
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11.3.4 Concordance between the QFN-gold assay and TST 
992 individuals had both a QFN and TST performed. The 2 by 2 contingency table of 
these results is shown in Table 20. The percentage agreement between the 2 tests was 
73% with a kappa statistic of 0.46. 11.5% of individuals had a discordant result with a 
positive TST and negative QFN assay, while a further 15.5% of individuals showed 
discordance with a positive QFN and negative TST 
Table 20: Contingency table of TST and QFN 
11.3.5 Factors contributing to TST and QFN-gold positivity 
Univariate and multivariate logistic regression analyses of factors contributing to TST 
positivity were performed (Table 21). The following factors were identified as being 
statistically significant in their association with a positive TST: age (for categories 
above 30yrs), having a past history of TB, sharing a room with a TB patient, being 
male and having 2 or more BCG scars. Of these factors only the first three were 
similarly associated with QFN-gold positivity, as shown in Table 22. Contrary to the 
result seen with TST having 2 or more BCG scars protected against QFN positivity 
with an OR 0.68 (0.53-0.85, P = 0.001). This effect was observed when the multiple 
logistic regression model was fitted to take into account potential socio-economic and 
educational confounders. 
 
 
 
 
TST POSITIVE 
 
TST NEGATIVE 
 
QFN POSITIVE 
 
 
343 
 
 
154 
QFN NEGATIVE 
 
114 381 
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VARIABLE 
 
TST UNIVARIATE ANALYSIS 
 
TST MULTIPLE ANALYSIS 
 OR (95% CI) 
 
P – value OR (95% CI) P – value 
Age Group         
       *<20 0  0  
        21-30 1.22 (0.95-1.58) 0.122 1.19 (0.91-1.55) 0.210 
        31-40 1.61 (1.21-2.13) 0.001 1.42 (1.06-1.90) 0.020 
        >41 1.73 (1.33-2.24) <0.001 1.57 (1.20-2.06) 0.001 
Sex (F) 0.72 (0.6-0.87) 0.001 0.72 (0.59-0.88) 0.001 
BMI     
       *<21 0  0  
        21-23.5 1.07 (0.79-1.43) 0.665 1.00 (0.74-1.36) 0.995 
        23.5-26.5 1.37 (1.03-1.82) 0.030 1.26 (0.95-1.71) 0.129 
        >26.5 1.42 (1.07-1.87) 0.014 1.29 (0.95-1.76) 0.108 
Secondary Education 1 (0.84-1.2) 0.05 0.98 (0.81-1.2) 0.824 
Diabetes  0.74 (0.32 – 1.66) 0.464   
BCG (≥ 2 scars) 1.4 (1.2-1.7) <0.001 1.4 (1.2-1.7) <0.001 
Past TB  2.94 (2.09-4.14) <0.001 2.7 (1.9-3.8) <0.001 
Share TB room 1.5 (1.2-1.8) <0.001 1.4 (1.2-1.7) <0.001 
Brick Wall  1 (0.8-1.2) 0.943     
Number residents 0.99 (0.96-1.03) 0.745   
Monthly house income 
(*Baseline) 
1 (1-1) 0.628   
Table 21: Logistic regression analysis of factors contributing to TST positivity  
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VARIABLE 
 
QFN UNIVARIATE ANALYSIS 
 
QFN MULTIPLE ANALYSIS 
 OR (95% CI) 
 
P – value OR (95% CI) P – value 
Age Group         
       *<20 0  0  
        21-30 1.6 (1.16-2.22) 0.004 1.39 (0.998-1.941) 0.051 
        31-40 2.32 (1.63-3.32) <0.001 2.02 (1.39 – 2.91) <0.001 
        >41 2.87 (2.07 – 3.99) <0.001 2.64 (1.88-3.71) <0.001 
Sex (F) 0.86 (0.68-1.07) 0.174   
BMI     
       *<21 0    
        21-23.5 0.91 (0.64-1.30) 0.619   
        23.5-26.5 0.99 (0.71-1.38) 0.949   
        >26.5 1.02 (0.73-1.42) 0.890   
Secondary Education 0.78 (0.62-0.97) 0.025 0.94 (0.73-1.21) 0.655 
Diabetes  1.87 (0.65-5.42) 0.246   
BCG (≥ 2 scars) 0.76 (0.61-0.94) 0.013 0.68 (0.53-0.85) 0.001 
Past TB  3.82 (2.55-5.74) <0.001 3.32 (2.18-5.05) <0.001 
Share TB room 1.71 (1.36-2.14) <0.001 1.60 (1.26-2.02) <0.001 
Brick Wall  0.89 (0.7-1.11) 0.370     
Number residents 0.98 (0.93-1.02) 0.302   
Monthly house income 
 
1 (1-1) 0.076 1 (1-1) 0.522 
Table 22: Logistic regression analysis of factors contributing to QFN positivity (*Baseline) 
108 
 
 
11.3.6 Factors contributing to discordance between QFN and TST 
On multiple logistic regression analysis the only factor which contributed to 11.5% of 
individuals being TST positive and QFN negative is having 2 or more BCG scars OR 
2.88 (1.91-4.07, P= <0.001). Having an age above 40 protected individuals from 
having a positive TST and negative QFN OR 0.51 (0.31-0.85, P=0.01)(Table 23)  
Table 24 shows factors contributing to QFN positivity and TST negativity, these 
include: female sex OR 1.67 (1.06-2.62, P=0.027) and age above 40 OR 2.45 (1.29-
4.67, P=0.006). As with factors contributing to QFN positivity once again we see a 
protective effect of having 2 or more BCG scars in preventing individuals from being 
QFN positive and TST negative. 
11.4 Discussion 
The Ventanilla population has a high rate of BCG vaccination, with over 85% of 
individuals having at least one BCG scar and more than 50% having 2 or more BCG 
scars.  
The manufacturer’s cut of value for a positive QFN assay (concentration of IFN-γ in 
corrected TB Antigen tube >0.35), was felt to be an appropriate cut off value to use in 
this population. Similarly the cut of value for a positive TST of 10mm (as 
recommended by Peruvian guidelines) was felt to be appropriate in this population. 
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VARIABLE 
 
UNIVARIATE 
 
MULTIPLE 
 OR (95% CI) 
 
P – value OR (95% CI) P – value 
Age Group         
       *<20 0  0  
        21-30 0.94 (0.59-1.51) 0.801 0.98 (0.60-1.59) 0.937 
        31-40 0.78 (0.46-1.35) 0.385 0.67 (0.39-1.17) 0.157 
        >41 0.58 (0.35-0.95) 0.031 0.51 (0.31-0.85) 0.010 
Sex (F) 0.93 (0.65-1.33) 0.695   
BMI     
       *<21 0  0  
        21-23.5 0.45 (0.18-1.12) 0.088 0.47 (0.18-1.22) 0.123 
        23.5-26.5 0.45 (0.18-1.15) 0.097 0.52 (0.19-1.39) 0.192 
        >26.5 0.41 (0.15-1.11) 0.081 0.50 (0.17-1.44) 0.198 
Secondary Education 1.18 (0.84-1.67) 0.340   
Diabetes  1.64 (0.45-6.02 0.457   
BCG (≥ 2 scars) 2.57 (1.77-3.72) <0.001 2.88 (1.91-4.07) <0.001 
Past TB  0.96 (0.55-1.68) 0.876   
Share TB room 0.93 (0.66-1.32) 0.702   
Brick Wall  1.08 (0.75-1.56) 0.683   
Number residents 0.95 (0.88-1.03) 0.230   
Monthly house income 
 
1 (1-1) 0.789   
Table 23: Univariate and Multivariate logistic regression analysis for factors predicting TST positivity and QFN negativity  (*Baseline) 
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VARIABLE 
 
UNIVARIATE 
 
MULTIPLE 
 OR (95% CI) 
 
P – value OR (95% CI) P – value 
Age Group         
       *<20 0  0  
        21-30 1.42 (0.72-2.82) 0.316 1.37 (0.69-2.73)  0.367 
        31-40 1.85 (0.91-3.78) 0.089 1.87 (0.91-3.83) 0.089 
        >41 2.44 (1.29-4.63) 0.006 2.45 (1.29-4.67) 0.006 
Sex (F) 1.75 (1.12-2.74) 0.014 1.67 (1.06-2.62) 0.027 
BMI     
       *<21 0    
        21-23.5 1.24 (0.28-5.46) 0.771   
        23.5-26.5 1.32 (0.30-5.87) 0.714   
        >26.5 2.40 (0.53-10.8) 0.256   
Secondary Education 0.69 (0.47-1.04) 0.074 0.85 (0.56-1.30) 0.454 
Diabetes  3.5 (1.06-1.55) 0.04 2.52 (0.74-8.65) 0.141 
BCG (≥ 2 scars) 0.71 (0.48-1.06) 0.094 0.67 (0.45-0.99) 0.046 
Past TB  0.77 (0.39-1.52) 0.456   
Share TB room 1.5 (1.01-2.22) 0.04 1.37 (0.92-2.05) 0.122 
Brick Wall  0.93 (0.62-1.40) 0.728   
Number residents 1.02 (0.94-1.1) 0.541   
Monthly house income 
 
1 (1-1) 0.484   
Table 24: Univariate and Multivariate logistic regression analysis for factors predicting QFN positivity and TST negativity (*Baseline) 
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When using past medical history as a surrogate for latent TB both the TST and QFN-
gold assay were suboptimal in diagnosing latent TB. When active TB was used as a 
surrogate, the QFN-gold assay was again limited. This is consistent with findings in 
other studies and meta-analyses. 
Both tests demonstrate a similar rise in sensitivity alongside a gradient of exposure. 
Using the “no known exposure” to TB group as a surrogate for absence of latent we 
can calculate a specificity of 64% for the TST and 65% for QFN-gold assay.  
The agreement between the two tests was 73% with a κ statistic of 0.46. Multiple 
studies have shown different levels of agreement and κ statistic depending on the 
population studied. Indeed the κ statistic is dependent on the underlying population 
prevalence of the measured outcome and so is not a useful measure to compare across 
studies.  
On multiple logistic regression analysis of factors contributing to TST and QFN 
positivity it is not surprising that past TB and sharing a room with a TB patient 
contribute to a positive test. If age is taken as a surrogate for community exposure to 
TB then once again both tests show rising odds ratios as the age group increases.  
Having 2 or more BCG scars contributed to a positive TST and also predicted 
discrepancy in having a positive TST and negative QFN assay. This is consistent with 
other studies which have shown the confounding effects of BCG vaccination on the 
TST, and the greater specificity of the IFN-γ assays which use RD1 region antigens 
exclusive to MTB.  
BCG vaccination showed a protective effect towards QFN positivity, suggesting that 
BCG vaccination protects against latent TB infection and not just TB disease. This is 
an exciting new finding which has not previously been shown in an adult population 
using the QFN assay. Previous paediatric and ELISPOT studies have shown a similar 
protective effect of BCG vaccination when latent TB is defined using an IFN-γ 
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assay.[140] The confounding effect of BCG vaccination on the TST has not allowed 
this finding to be discovered prior to the use of IFN-γ assays.  
Both tests have their limitations. The QFN does not always test positive in individuals 
with a past history of TB or active TB and was not shown to be associated with recent 
exposure history in those circumstances where an individual was QFN positive and 
TST negative. The TST, however was shown to be confounded by BCG vaccination 
and in a heavily BCG vaccinated population such as Ventanilla this would result in 
false positives for latent TB. 
The results of this analysis suggested that, in the absence of a gold standard test for 
latent TB the QFN assay would be the best available test to define latent TB and train 
machine learning classifiers. If latent TB is defined by the QFN assay then we already 
begin to see evidence which changes our perception of BCG vaccination and TB 
epidemiology. 
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12 PROTEOMIC PROFILES IN LATENT TUBERCULOSIS 
12.1 Introduction 
1.7 billion Individuals (one third of the world’s population) are infected with TB; 
providing many reasons why we need to be able to identify people with latent TB. 
Latent TB provides a reservoir of infection from which active TB can develop, many 
believe that by detecting cases of latent TB and providing treatment we can decrease 
the pool of individuals who could reactivate later in life. Latent TB investigations also 
allow us to contact trace individuals exposed to active TB and potentially offer 
prophylaxis before they themselves become active cases, as well as aiding 
epidemiological investigations. Health care professionals who are constantly exposed 
to TB will also benefit from screening tests for latent TB.  
In the previous chapter it was identified that neither the TST nor IFN-γ assay 
distinguished latent from active TB. At present we rely on clinical symptoms and 
sputum smear/culture to make this distinction. There is also a lack of a gold standard 
test for latent TB, with surrogates used to reflect the immune status of an individual.  
Proteomic signatures were shown to provide an accurate reflection of the host 
pathogen interaction in active TB; the prospect of distinguishing latent TB from both 
active TB and the absence of TB altogether will now be explored. The search for this 
signature was conducted both in the plasma and in the intracellular proteome using 
peripheral blood mononuclear cell (PBMC) lysates. 
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12.2 Methods 
12.2.1 Latent TB participant recruitment 
Healthy controls with no respiratory symptoms were recruited from households who 
did not have active TB cases resident, and proportionally covered the same 
geographical area of the shanty town as active TB households. A TST and IFN-γ 
assay were performed to assess latent TB status of all individuals. Blood was also 
taken for proteomic studies.  
12.2.2 Latent TB Sample processing 
As well as aliquoting plasma from blood tubes after centrifugation, a proportion of the 
samples were treated on columns of ficcoll in order to harvest PBMCs. The 
concentration of PBMC lysate applied to chips was standardised by diluting all 
samples to a final concentration of approximately 150µg/ml with a lysis buffer.  
12.3 Results 
12.3.1 Latent TB Demographics  
150 healthy controls were recruited (Table 25), 63 with latent TB and 87 with no 
latent TB, as defined by the QFN assay. PBMCs were obtained from 18 individuals 
with latent TB and 27 with no latent TB. The median age of individuals and the 
proportion of individuals with a past medical history of TB were greater in the latent 
TB group than in the non latent group. This would reflect the greater community 
exposure to TB amongst the older age group. 
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12.3.2 Plasma latent TB: principal component analysis 
The PCA plot reflecting the whole plasma proteome of latent TB individuals against 
non latent TB (Figure 24), shows no evidence of spatial discrimination between the 
Blue spots (latent TB) and Red spots (no latent TB). Both coloured spots are 
randomly distributed in space. Similarly the heat map comparing both groups (Figure 
25) does not show an obvious area of up or down regulation.  
           
Figure 24: PCA plot latent TB against no TB using crude plasma 
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Table 25: Demographic details of participants in latent TB study  
 
Plasma latent TB 
 
Plasma no latent 
 
 
 
PBMC latent TB 
 
 
 
PBMC no latent TB 
  
Numbers 
 
62 
 
87 
 
 
18 
 
 
27 
 
Median Age (IQR) 
 
38 (29-48) 
 
29 (19-37) 
 
 
36 (27-50) 
 
 
29 (19-34) 
 
Female (number(%)) 
 
40 (65%) 
 
58 (67%) 
 
 
13 (72%) 
 
 
16 (60%) 
 
Mean BMI (SD) 
 
26.5 (3.8) 
 
25.6 (4.5) 
 
 
25 (3.1) 
 
 
24 (3) 
 
TB tube [IFN] (IQR) 
 
4.01 (1.06-8.6) 
 
0.03 (0.01-0.07) 
 
 
3.2 (1.1-4.0) 
 
 
0.01 (0.01-0.07) 
 
Past TB (number (%)) 
 
 6 (4) 
 
 0(0) 
 
 
3 (16%) 
 
 
0(0) 
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                                                 No Latent TB                                         |                       Latent TB 
                     
Figure 25: Heat map latent TB against no TB using crude plasma
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12.3.3 Univariate analysis: Discriminatory peaks between latent TB and no 
latent TB in crude plasma. 
The results of the Mann Whitney U tests carried out to determine statistically 
significant differences between latent and no latent TB participants are shown in 
Table 26. No peaks achieved a discriminatory potential with area under the ROC 
curve > 0.8 or <0.2. Peaks are therefore shown with an ROC > 0.6 or <0.4. Compared 
to the previous analysis with active TB the P values are now lower. The most 
discriminatory peak is at 11.4kDa, with a p-value of 2x10-5 and an area under the 
ROC curve of 0.63. 
 
m/z 
 
Mean Intensity  
 
P-value 
 
ROC 
 
 
11430.12 1.434336 2.04E-05 0.631812 
 
8458.144 10.14458 1.25E-04 0.636139 
 
13970.95 2.053488 1.95E-04 0.633271 
 
13767.59 7.515978 7.39E-04 0.61893 
 
4671.422 22.8749 7.87E-04 0.390882 
 
8601.441 15.34143 9.95E-04 0.388014 
 
8558.103 57.94042 0.001131 0.620339 
 
4279.35 13.09856 0.003257 0.601721 
 
9552.786 
 
12.08696 
 
0.004399 
 
0.405223 
 
Table 26: Peaks that discriminate latent TB from no TB 
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12.3.4 11kDa: mean peak intensities of healthy controls with and without latent 
TB. 
Figure 26 shows the area of the spectrum between 11 and 12kDa with mean peak 
intensities of all the peaks in this region. The mean intensity for latent TB participants 
(QFN pos) is shown in blue and non latent TB (QFN neg) individuals in red. On 
average individuals with latent TB have higher levels of most peaks present in this 
region, the intensities of the peaks are however not as high in this region as seen with 
active TB patients where this peak was identified as SAA. The errors bars in this 
figure reflect a significant difference in levels of this complex of peaks between latent 
TB and no latent TB. 
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Figure 26: Average peak intensities for latent TB and no TB in the 11.5kDa region 
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12.3.5 PBMC lysate spectrum 
Before the lysis process PBMCs were washed 3 times to remove any plasma contamination 
and to ensure the resulting spectrum is an accurate representation of the intracellular 
proteome. Figure 27 shows the pattern and intensities of peaks in the PBMC lysate to be very 
different to that produced from the plasma of the same individual.  
 
Figure 27: Representative spectra from crude plasma and PBMC lysates 
12.3.6 Latent PBMC lysate: principal component analysis 
Figure 28 shows the PCA plot comparing the spectra from PBMC lysates of individuals with 
latent TB(blue) and no latent TB(red). Although discrimination is not as clear as has been 
seen in previous plots, latent TB individuals do form a horizontal cluster at the bottom of the 
plot while non latent TB individuals form a more vertical cluster towards the left of the plot. 
There is a difference in the distribution of spots with PBMC lysates compared to the totally 
random distribution seen with plasma profiles in latent TB. 
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Figure 28: PCA plot latent TB against no TB using PBMC lysate profiles 
12.3.7 Univariate analysis: Discriminatory peaks between latent TB and no latent TB in 
PBMC lysates. 
Peaks which discriminate latent TB from no latent TB in PBMC lysates are shown in Table 
Table 27. No individual peak has a discriminatory power to produce an area under the ROC 
curve of >0.8 or <0.2. However 17 peaks achieved an area under the ROC curve of >0.6 or 
<0.4. The peak at 9.1kDa has the greatest discriminatory value and also the highest intensity, 
representative spectra of this peak are shown in Figure 29. 
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Mass/Charge 
 
 
Mean Intensity 
 
P-value 
 
ROC 
 
9112.31 34.6968 0.001306438 0.6933 
 
18668.50 2.6042 0.00170687 0.6892 
 
40694.57 0.1295 0.003996286 0.6800 
 
9532.63 79.7613 0.014730812 0.6574 
 
41935.16 0.1071 0.016976261 0.6337 
 
19821.12 1.2327 0.018207698 0.6574 
 
57469.94 0.4545 0.019516653 0.6522 
 
17961.79 3.4994 0.019970877 0.6614 
 
11772.37 
 
20.1122 0.020907078 0.6377 
 
4660.42 85.1198 0.023948805 0.6481 
 
37692.33 0.2210 0.025044652 0.6337 
 
5662.17 16.3534 0.030529633 0.6429 
 
5369.28 19.8793 0.035481222 0.3651 
 
18480.60 2.6352 0.037804432 0.6377 
 
118283.46 0.08738 0.037804432 0.6059 
 
8892.85 12.2685 0.040255799 0.6192 
 
19643.54 0.9256 0.043732889 0.6059 
 
28593.88 2.3494 0.044640758 0.5925 
Table 27: Discriminatory peaks latent TB against no TB using PBMC lysate profiles 
 
124 
 
           
Figure 29: Representative spectra of peak at 9.1kDa 
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12.3.8 Crude Plasma: Discrimination of active TB against latent TB 
A combined database was created of all individuals with Active TB (155) and individuals 
with Latent TB (113) of which 52 were healthy controls and 61 unhealthy controls. As all 
spectra had been generated under the same conditions and with the same laser energy they 
were analysed together in one experiment. Figure 30 shows the PCA plot representing the 
ability to distinguish active TB from latent TB using crude plasma. The appearance of this 
plot is very similar to that seen when comparing active TB to unhealthy controls (54% of 
whom had latent TB). The Univariate analysis showing peaks which discriminate between 
active TB and latent TB (Table 28), shows a similar combination of peaks in the 11.5kDa 
region as was seen when comparing active TB to unhealthy controls. 
                       
Figure 30: PCA plot active TB against latent TB using crude plasma profiles 
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m/z 
 
Mean Intensity 
 
P value 
 
ROC 
 
 
5811.16 4.80 9.55E-51 0.88 
11479.10 8.50 4.80E-50 0.87 
11628.65 8.54 2.08E-49 0.87 
11540.23 12.99 2.26E-47 0.87 
5732.36 3.67 1.32E-45 0.86 
11433.03 7.61 9.52E-46 0.86 
11691.84 24.20 2.44E-46 0.85 
5759.58 6.73 1.17E-45 0.85 
11385.55 4.33 7.15E-47 0.85 
5837.56 13.11 5.27E-43 0.84 
5941.09 3.21 7.71E-41 0.83 
10834.38 1.40 9.57E-37 0.82 
11898.50 
 
3.92 
 
3.50E-34 
 
0.80 
 
 
Table 28: Discriminatory peaks for active TB against latent TB using crude plasma profiles 
 
12.3.9 Performance of support vector machines in latent TB. 
Using whole crude plasma spectra, a machine learning classifier could only discriminate 
latent TB from the absence of TB with a sensitivity of 66% and accuracy of 77% (Table 29). 
The performance of the classifier improved considerably when PBMC lysates were used; 
sensitivity 87% and accuracy 84%.  
The best SVM performance was achieved when discriminating active TB from latent TB, 
with a sensitivity of 90% and accuracy of 89%. 
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Comparison 
 
 
Accuracy 
 
Sensitivity (STD) 
 
Specificity (STD) 
 
Plasma (Latent : No Latent) 
 
0.77 (0.05) 
 
0.67 (0.09) 
 
0.84 (0.06) 
 
PBMC (Latent : No Latent) 
 
0.84 (0.09) 
 
0.87 (0.18) 
 
0.83 (0.09) 
 
Plasma (Active : Latent) 
 
0.89 (0.02) 
 
90 (0.03) 
 
0.89 (0.04) 
Table 29: SVM performance in latent TB diagnostics 
12.4 Discussion 
Latent TB was not well discriminated from the absence of latent TB in crude plasma 
specimens. This was reflected in the PCA plot, the discriminatory peaks table and in the 
performance of the SVM. In the previous chapter the absence of a gold standard investigation 
for latent TB was discussed, thus making training of a machine learning classifier difficult 
from the outset.  
In active TB we would expect an aggressive host-pathogen interaction whereby the host is 
attempting to control infection and the pathogen actively causing damage to host tissue. In 
latent TB, however, we expect the patho-physiological reactions to be taking place in the 
tuberculous granuloma where the host attempts to contain infection. It is not very surprising 
with this focal localised host-pathogen reaction that there are few signs of a “spill-over” seen 
in the plasma proteome.  
Once again it was interesting to observe the acute phase protein SAA was the most 
discriminatory marker present in the plasma of individuals with latent TB, suggesting this 
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marker is not only important in the acute phase of TB infection but also reflects ongoing 
control of infection in latency. 
The PBMC signature however succeeded in discriminating latent TB from no TB with 
greater accuracy and sensitivity albeit with fewer participants studied. The ability of SELDI-
TOF mass spectrometry to detect patterns of proteins in biological solutions with low 
concentrations has been unique in identifying these important intracellular patterns. That the 
host has battled against TB at some point in the past is reflected in the nature of the 
lymphocytes and monocytes present in the PBMC population. 
When comparing active TB with latent TB we achieved our best classifier for crude plasma. 
The pool of individuals with latent TB was taken from our cohort of healthy and unhealthy 
controls, who tested positive on the QFN assay. A clear crude plasma proteome has not been 
defined which discriminates latent TB from the absence of latent TB and caution must 
therefore be taken when comparing latent TB with Active TB. It is important to note that the 
PCA plot for this comparison was similar in pattern to that achieved with active TB and 
unhealthy controls with similar potential biomarkers. It is therefore likely that the same 
markers which make it possible to discriminate active TB patients from unhealthy controls 
will also allow us with greater accuracy to discriminate active TB patients from healthy 
community controls with latent TB. Nevertheless it is important to note that where the IFN-γ 
assay and TST could not distinguish active TB from latent TB, proteomic signatures as a 
reflection of host pathogen interaction are able to do this. 
In general we can see that although the plasma proteome is useful in the discrimination of 
active TB from other forms of TB, finding a signature for latent TB will be limited while we 
struggle to define a gold standard for latent TB. The search for the latent TB signature may 
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also need to be conducted in the cells involved in the control of disease, or indeed in the 
granuloma itself. 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
13 DISCUSSION 
Distinct plasma proteomic profiles were defined in active TB which allowed discrimination 
from unhealthy controls. These profiles derived from SELDI-TOF mass spectrometry were 
used to identify patterns which discriminate between the 2 groups using machine learning 
algorithms. From these patterns potential biomarker peaks were characterised and one 
potential protein biomarker identified. 
Samples were collected and processed using standard operating as well as automated 
procedures. QC measures were taken to ensure only high quality data were analysed and 
analytical bias reduced. These measures matched and in some circumstances superseded CV 
published for other SELDI-TOF studies.  
The study was able to define active and unhealthy controls using smear microscopy and 
MODS cultures. To ensure SVM classifiers were correctly trained unhealthy controls had 
multiple sputum samples processed and were revisited in the community within 1year of 
symptom onset to ensure they had not developed TB. Despite these measures it is still 
possible for an unhealthy control participant to present with subclinical, self-resolving TB 
which is not picked up by our laboratory investigations. Although this would be a rare 
occurrence, a single misidentified individual in a SVM would significantly impair 
performance of the classifier. 
The very nature of the clinical presentation of TB (a chronic inflammatory disease) makes it 
difficult to find appropriate controls with similar symptoms as most other respiratory 
infectious diseases have a much shorter time course. In this study TB patients inherently have 
more days of fever, night sweats and weight loss than unhealthy controls with respiratory 
symptoms. This chronicity at baseline results in TB patients with on average lower BMI than 
unhealthy controls. This was a limitation of the study which could not be avoided in view of 
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the nature of TB and the need for clinically relevant controls. The unhealthy controls selected 
in this study were the very individuals who presented with symptoms that required exclusion 
of TB. 
The evaluation of clinical symptoms in SELDI studies is something that has often been 
neglected and is of fundamental importance.[114] Many studies have searched for biomarkers 
in cancer patients who, like TB patients, are in a catabolic weight losing state. Many proteins 
(albumin in particular) will be influenced by the nutritional state of the patient and it was 
clear on evaluating the crude plasma proteome that BMI was a confounding factor. Without 
this clinical assessment it would be possible to create pattern recognition algorithms that are 
merely a surrogate for nutritional status. Fractionation of the plasma proteome produced 
classifiers which were more sensitive, specific and were not confounded by nutritional factors 
such as the BMI. Fractionation gives a deeper proteome, revealing previously unseen 
potential biomarkers which overcome the confounding effects of nutritional status.  
Two separate SELDI studies have identified SAA as the most striking potential biomarker for 
TB. For over one hundred years it has been recognised that chronic mycobacterial infections 
are associated with amyloidosis.[141-143] SAA is an acute phase protein induced by 
Macrophage derived Interleukin-1 (IL-1) and is a sensitive marker of macrophage 
stimulation. Different mycobacteria stimulate SAA production to different extents. SAA has 
also been shown to stimulate Matrix Metalloproteinases (MMPs) which play a fundamental 
role in the tissue destruction and cavity formation seen in TB.[144, 145] 
Interleukin-2 (IL-2) is also a pivotal cytokine in cell mediated immunity. In a study by Rossi 
et al looking at the inflammatory protein profile during systemic interleukin-2 (IL-2) 
administration, SAA and CRP were consistently upregulated post 4 doses of IL-2.[146] 
Cytokines and chemokines are below the detection limits of SELDI but the changes detected 
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in acute phase proteins as a result of disease specific cytokine changes can provide valuable 
detectable surrogate biomarkers reflecting the underlying pathophysiology.  
Multiple variants of SAA have been detected as potential biomarkers in other diseases and 
these variants could reflect disease specific post-translational modifications related to the host 
pathogen response in TB. In a chronic disease like TB the duration of time will produce some 
changes and modifications to the pattern of circulating acute phase proteins. Although 
unhealthy controls did have SAA present in the proteome the pattern of the peaks was 
markedly different to that seen in TB. It was often noted that a potential biomarker was seen 
in a cluster of peaks and not a single peak alone (4.4-4.8 kDa), once again suggesting that TB 
may not just be characterised by specific proteins in the blood but by specific variants of 
these proteins. Further work needs to be conducted to identify these other potential biomarker 
peaks. 
The heterogeneity of TB proteomic profiles provides a striking reminder of how active TB is 
not a single clinical disease state. As well as differences in host pathogen interactions, 
individuals also present at different stages in the natural history of TB infection. A single 
proteomic profile or biomarker will not correctly identify all TB patients and the need to 
accept multivariate protein panels as diagnostic tools maybe the way forward. 
Ten patients with active TB were smear microscopy negative on their first sputum sample but 
were culture positive. All ten of these patients were correctly classified by the SVM on the 
basis of proteomic profiles. This has encouraging implications for the potential benefits of 
biomarkers derived from these signatures compared to smear microscopy as screening tests 
for TB. A protein based biomarker screening test has further economic and social benefits in 
the diagnosis of TB, with the potential of inexpensive, simple and immediate point of care 
screening tests. It is important to remember however, that the sputum culture is still necessary 
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in order to give information about drug susceptibility and genotype of the organism. A 
protein panel resulting from SELDI studies has been developed and is being investigated for 
the early diagnosis of ovarian cancer.  
The proteomic profiles did not discriminate latent TB from the absence of latent TB with a 
large degree of accuracy when crude plasma profiles were used. In order to investigate 
proteomic profiles in latent TB we first set out to define latent TB using currently available 
diagnostic tests, with the limitation that no gold standard test exists. Through our statistical 
analysis we investigated the TST and QFN assay and investigated optimal cut off values for 
these tests in our population. The reported lack of exposure to TB was used as a surrogate for 
the absence of latent TB in calculating cut of values in our ROC analysis. The general 
prevalence of TB, levels of poverty and overcrowding within this population, would make it 
very difficult to conclusively define a group of individuals with no known TB contact. This 
poses a potential limitation of our ROC analyses. As we were limited in our definition of 
latent TB, training of a SVM was potentially flawed by mislabelled data. The 
pathophysiology of latent TB also makes it very difficult to hunt for a discriminatory 
signature in crude plasma. 
Proteins are often involved in signalling networks and so small changes in the concentration 
of a protein can be amplified to exert the desired effect. In a disease state tissue leakage 
proteins maybe present in femto-molar concentrations in the plasma, and will not easily be 
detected in a solution with such a large dynamic range. Latency further complicates the 
situation by being a quiescent state where our knowledge of host pathogen interaction is 
largely based on stimulation of the host immune response. 
The short pilot study performed on PBMC showed more promising results in discriminating 
latent TB from the absence of latent TB. Whether TB specific cells are present in PBMCs is 
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debatable but cellular lysates do not have the same dynamic range as plasma. The likelihood 
of detecting small changes in low abundance proteins is therefore greatly improved. A further 
study would need to be conducted to isolate and stimulate monocytes from individuals with 
and without latent TB and investigate the proteomic profiles of cellular lysates. SELDI-TOF 
experiments have also been conducted on histological samples and the potential of 
investigating lung biopsies from individuals with latent TB may give us further insights into 
the pathophysiology of latent disease control. 
Although proteomic profiles did not accurately discriminate latent TB from the absence of 
TB they were able to discriminate latent TB from active TB. This differentiates the proteomic 
profile from the TST and IFN-γ assays which do not discriminate active TB from latent or 
past infection, which has extensively limited their use in the diagnosis of active TB.  
A further, exciting and incidental finding of this study was the statistical analysis that 
revealed a protective effect of BCG vaccination against TB infection (latent) as opposed to 
TB disease (active). The TST is confounded by BCG vaccination and so is limited in any 
investigation to observe the protective effects of BCG. By using the QFN assay in a heavily 
BCG vaccinated community, we have been able to demonstrate BCG protection against latent 
TB. This effect is not confounded by socio-economic factors which may contribute to health 
seeking behaviour. Not only does this finding have implications in the public health use of 
BCG vaccination, it also gives us promising ways in which to assess future potential vaccines 
for TB. 
Further work needs to be conducted to investigate the potential of proteomic profiles as a 
diagnostic tool in tuberculosis. Discriminatory peaks that have been characterised need to be 
identified and validated by other proteomic platforms before they can be investigated as 
potential biomarkers for disease. 
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The rate of HIV amongst Peruvian TB patients is less than 5% and so the effects of co-
infection on proteomic profiles were not studied in this population. Any diagnostic test for 
TB in the developing world needs to be validated in HIV and TB co-infected individuals. 
TB is a heterogeneous, chronic disease where the host-pathogen dynamics are constantly 
changing. Time series proteomic data in newly diagnosed TB patients would give us insight 
into how the proteome varies over the course of infection. The effects of treatment on 
potential biomarkers could also be observed and an assessment made of their prognostic 
potentials.  
The study of a heterogeneous disease in large populations gives us clinically relevant 
information which would not be derived from the study of homogeneous cell models of 
disease. Whilst translational research is often based on laboratory and animal studies being 
applied to human subjects, proteomic profiles start by identifying relevant proteins in the host 
and allow us further to assess their role in laboratory models. The role of SAA in TB could 
give us important insights into the protein networks that facilitate immunity. 
Whilst to date SELDI-TOF studies have largely identified host proteins, an ideal diagnostic 
tool would be one that could identify a combination of host and pathogen proteins. The use of 
SELDI-TOF profiling of sputum specimens is an area which is gradually developing. The 
molecular wall of MTB is unique in its characteristic lipid bilayer, and using specific 
biochemical properties of SELDI-TOF chip surfaces, this platform could potentially be used 
to identify discriminatory proteins of host and pathogen origin in the sputum of active TB 
patients. 
Our knowledge of the different clinical TB subpopulations and evolution of infection in 
individuals is still very poor. The outcome of infection with TB is determined by interactions 
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which occur at a molecular, cellular, anatomical and population level. Supervised machine 
learning can give us insights into patterns of response observed in the host and the pathogen 
using microarray, proteomic and genomic techniques. Systems biology can provide 
mathematical modelling techniques to assess how interactions at one level affect interactions 
at other levels[147]. Gradually with the tools available to modern science we can gain a 
deeper understanding of the complexity of TB, a disease which mankind has battled for 
centuries. 
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